Митохондриальная ДНК (mtDNA) в качестве жидкого биомаркера в нейродегенеративных расстройствах: систематический обзор.

INTRODUCTION

In the last decades, mitochondrial dysfunction has emerged as a pathological hallmark of several neurodegenerative conditions, including Parkinson's disease (PD) [ 1 ], Alzheimer's disease (AD) [ 2 ] and amyotrophic lateral sclerosis (ALS) [ 3 ].

Several mechanisms of interaction between mitochondrial damage and neurodegeneration have been hypothesized. In PD, mitochondrial function can be affected by both genetic and environmental background, such as the presence of mutations in the PINK1/PRKN genes or exposure to neurotoxins (e.g. MPTP and rotenone). Evidence from PD experimental models showed that α‐synuclein aggregation is associated with inhibition of respiratory complex I, leading to impaired mitochondrial fusion and fission and, more generally, loss of mitochondrial quality control systems [ 1 ]. Conversely, altered mitophagy and increased oxidative stress induce lipid peroxidation and may increase γ‐secretase activity, leading to accelerated Aβ accumulation and the formation of hyperphosphorylated tau aggregates in AD [ 4 ]. Mitochondrial dysfunction, together with alterations in other cellular systems (e.g. nucleocytoplasmic and vesicular transport, DNA/RNA repair and metabolism, protein homeostasis) and non‐cell autonomous mechanisms (excitotoxicity, glial function) has emerged over the years as a possible player in the pathogenesis of ALS, also through the discovery of mutations in genes associated with each of these functions [ 5 ]. Beyond neurodegeneration, mitochondrial damage and subsequent mitochondrial DNA (mtDNA) leakage into the cytoplasm has been proposed as the main mediator of the neuroinflammatory profile which characterizes ALS [ 6 ]. In addition, defective mitochondrial bioenergetics is closely linked to the “cellular senescence” observed during ageing [ 7 ].

The defective production of ATP can induce loss of mitochondrial membrane integrity and permeabilization of the mitochondrial outer membrane. This leads to the release of mtDNA in the cytoplasm, which in turn can activate the cGAS–STING inflammatory pathway [ 8 ]. A fraction of mtDNA is instead released into the bloodstream as circulating cell‐free mtDNA (ccf‐mtDNA) or embedded in vesicles, where it acts as a pro‐inflammatory factor, thus spreading to other tissues an inflammatory‐degenerative vicious cycle [ 9 ]. This detrimental process has also been implicated in the pathogenesis of the progressive stage of multiple sclerosis (MS) [ 10 ], where neurodegeneration is the prominent pathological feature.

The key regulatory role of mtDNA in the neurodegenerative and neuroinflammatory scenarios paves the way for the development of mitochondria‐targeted therapeutic strategies with potential neuroprotective effects. Emerging evidence also suggests that neurodegenerative diseases are associated with mitochondrial dysfunction in peripheral cells, such as leukocytes and skin fibroblasts [ 11 , 12 ]. Altered mtDNA abundance (mtDNA copy number, mtDNA‐CN), integrity (mtDNA heteroplasmy, somatic mutations and deletions, collectively referable as “mtDNA damage”) and epigenetic profile (methylation) in cerebrospinal fluid (CSF) and peripheral blood may thus discriminate patients from healthy controls (HC) and inform about the diagnosis and prognosis in several neurodegenerative diseases.

However, previous studies investigating mtDNA parameters in patients' biofluids showed inconsistent results. Some authors reported lower mtDNA‐CN and/or ccf‐mtDNA in patients affected by different neurodegenerative disorders than controls, while others found unchanged or even increased mtDNA levels in patients compared to healthy subjects. Here, we aim to address this issue by providing a clinician‐oriented, comprehensive overview of the current evidence assessing CSF and blood mtDNA signatures (copy number, damage and methylation) as diagnostic and prognostic biomarkers in PD, AD and ALS. MS was also included as a paradigm of chronic neuroinflammation leading to secondary neurodegeneration [ 13 ]. This is preceded by a concise guide describing the methodologies currently adopted to characterize mtDNA.

Amplification and sequencing of mtDNA: traditional methods and recent advances

The study of mtDNA involves multiple and complementary methodologies tailored for the analysis of different types of alterations, including single nucleotide variants (SNV), small insertions and deletions (INDELs) and large rearrangements. These mutations can either affect all mtDNA molecules in a cell (homoplasmy) or a proportion of them (heteroplasmy). Of note, the heteroplasmy percentage can vary between cells in the same tissue or from organ to organ [ 14 ]. mtDNA methylation profile can also be analyzed with specific assays (Table  1 ).

TABLE 1 Methods of election for the analysis of the different types of mtDNA alterations and methylation profile investigated as putative biomarkers in neurodegenerative diseases. SNV and heteroplasmy Small and multiple deletions Complex rearrangements Copy number (cellular mtDNA) and concentration (ccf‐mtDNA) mtDNA methylation status Advantages Drawbacks Short‐read NGS X X
‐ Detects SNV with low heteroplasmy (1%–2%)
‐ Deep‐coverage of mtDNA

‐ Deletions overestimation
‐ Short‐read does not allow reconstruction of rearrangements
‐ Under or over‐estimation of mtDNA methylation status
TGS X X X
‐ Detection of deletions and complex rearrangements
‐Detection of mtDNA methylation status
‐ Low depth of coverage (only detects SNVs with heteroplasmy over 5%) qPCR X X ‐ Low cost
‐Susceptible to PCR bias (inhibitors)
‐ Normalization issues (standard curve or reference gene)
ddPCR X X
‐ Absolute quantification
‐ High sensitivity and reproducibility
‐ Resistance to PCR bias (inhibitors)
‐ High cost MS‐HRM X
‐ Simplicity
‐ High reproducibility and low cost
‐ Relative methylation estimates
Note : “X” indicates that the method is suitable for evaluating the corresponding mtDNA parameter. Abbreviations: ccf‐mtDNA, circulating cell‐free mtDNA; ddPCR, droplet digital polymerase chain reaction; MS‐HRM, methylation‐sensitive‐high resolution melting; NGS, next‐generation sequencing; qPCR, quantitative (real time) polymerase chain reaction; SNV, single nucleotide variants; TGS, third generation sequencing.

Methods of election for the analysis of the different types of mtDNA alterations and methylation profile investigated as putative biomarkers in neurodegenerative diseases.

‐ Detects SNV with low heteroplasmy (1%–2%)

‐ Deep‐coverage of mtDNA

‐ Deletions overestimation

‐ Short‐read does not allow reconstruction of rearrangements

‐ Under or over‐estimation of mtDNA methylation status

‐ Detection of deletions and complex rearrangements

‐Detection of mtDNA methylation status

‐Susceptible to PCR bias (inhibitors)

‐ Normalization issues (standard curve or reference gene)

‐ Absolute quantification

‐ High sensitivity and reproducibility

‐ Resistance to PCR bias (inhibitors)

‐ Simplicity

‐ High reproducibility and low cost

Note : “X” indicates that the method is suitable for evaluating the corresponding mtDNA parameter.

Abbreviations: ccf‐mtDNA, circulating cell‐free mtDNA; ddPCR, droplet digital polymerase chain reaction; MS‐HRM, methylation‐sensitive‐high resolution melting; NGS, next‐generation sequencing; qPCR, quantitative (real time) polymerase chain reaction; SNV, single nucleotide variants; TGS, third generation sequencing.

Currently, short‐read next‐generation sequencing (NGS) has substituted traditional sequencing methods and is now primarily employed for the detection of single point mutations, with robust confidence in the assessment of heteroplasmy degree [ 15 ]. However, its use for the detection of mtDNA rearrangements/deletions is limited by preparatory steps consisting of DNA fragmentation into small molecules (150‐300 bp reads) used as a template for sequencing, resulting in the loss of circular genomic contiguity and consequent difficulties in reconstructing structural changes [ 16 ]. Moreover, short‐read NGS techniques rely on mtDNA amplification via polymerase chain reaction (PCR) prior sequencing, which guarantees an extremely deep coverage (i.e. number of times that a given locus is sequenced with NGS data), but might introduce deletions overestimation because of preferential amplification of short amplicons [ 15 ].

Recent advancements in NGS technology, based on long‐read sequencing (also called third‐generation sequencing, TGS), hold the potential to address these limitations. Long‐read sequencing generates DNA molecules spanning several kilobases in length. As a result, the entire mitochondrial genome of ~16.6 kb can be sequenced in a single read. Two methodologies for long‐read sequencing are currently available, PacBio and Oxford Nanopore Technology (ONT) [ 17 ]. So far, only ONT has been employed in studies evaluating mtDNA as putative biomarkers in neurodegenerative diseases [ 18 ]. This approach is based on the passage of long DNA molecules through a “nanopore” embedded in an electric field, which causes a current perturbation once each nucleotide drives through [ 19 ]. TGS tools offer several advantages: (i) enhanced analysis of heteroplasmic deletions within a single read; (ii) detection of multiple deletions; (iii) identification of complex rearrangements, such as duplications [ 20 ]. However, drawbacks of this technology include lower sensitivity in detecting SNV and small INDELs, as well as heteroplasmy levels lower than 5%. Nevertheless, TGS is currently being implemented with innovative chemistries, sequencers and bioinformatic tools to boost accuracy of mtDNA variant calling [ 20 ]. TGS technologies have now been used also to directly measure mtDNA methylation status [ 21 , 22 , 23 ], thus overcoming the limitations associated with conventional methodologies [ 24 , 25 ].

mtDNA may also undergo quantitative changes, both at cellular (mtDNA‐CN) and cell‐free (ccf‐mtDNA) levels. These alterations could be evaluated through innovative PCR methods. In the last decades, real‐time quantitative PCR (qPCR) has been the method of choice for the quantification of mtDNA‐CN. This technique allows the amplification of DNA molecules in real time with fluorescent intercalants or target‐specific probes, monitoring the fluorescence as DNA amplicons are generated. qPCR requires normalization to controls (either a reference gene or a standard curve), allowing only relative quantification [ 26 ]. Differently, the newest droplet digital PCR (ddPCR) is based on a water–oil emulsion droplet system. Each reaction is partitioned and carried out individually: at an end‐point threshold droplets will be scored as either positive (+ target molecule) or negative (− target molecule). ddPCR provides absolute quantification of the DNA templates, which correlates with higher sensitivity, precision and improved reproducibility [ 27 ]. Beyond the difference in sensitivity, both approaches quantify mtDNA levels with the same rationale, i.e. the ratio of specific mitochondrial genes (usually located in mtDNA minor arc where deletions are rare, e.g. MT‐ND1 or D‐loop region) to a nuclear single‐copy gene (e.g. B2M or BAX ) [ 28 , 29 , 30 , 31 ]. In addition, multiplex assay also allows parallel quantification of mtDNA‐CN and deletions [ 32 ].

METHODS

The study protocol was registered in PROSPERO (ID: CRD42023460473) and followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guidelines [ 33 ].

Search strategy and inclusion/exclusion criteria

A search of MEDLINE (via PubMed), Embase, Scopus and Web of Science was conducted for original studies with no restriction on publication date (up to 1st October 2023‐date of database search). Specific search terms for each disease considered in the study (AD, PD, ALS) were used to isolate research in these three areas, excluding other neurodegenerative diseases that would have been included using general terms such as “neurodegeneration”. The same method was applied for MS. The complete search strategy is available in Table  S1 .

Details on inclusion and exclusion criteria were reported according to the Population, Intervention, Comparison, Outcomes and Study design (PICOS) framework (Table  2 ) [ 34 ]. Only studies reporting original data were included. Review articles were excluded but retained for general considerations.

TABLE 2 A priori defined inclusion and exclusion criteria according to the Population (P), Intervention (I), Comparison (C), Outcomes (O) and Study design (S) (PICOS) framework. Inclusion criteria P Patients of any age I Measurement of mtDNA abundance (mtDNA‐CN, ccf‐mtDNA), variant burden (heteroplasmy, deletion ratio) and methylation in blood or cerebrospinal fluid C Healthy subjects or neurological controls O

Main outcome : Subjects with a diagnosis of a neurodegenerative disease, including PD, AD, ALS, MS

Secondary outcome : Different clinical subtypes of each neurodegenerative disease
S
Studies on human subjects
Fully‐reported observational studies (prospective or retrospective) and cross‐sectional studies
Studies written in English
Exclusion criteria I
Measurement of mtDNA abundance and variant burden in other tissues/biosamples and postmortem ventricular cerebrospinal fluid
Assessment of mtDNA haplogroups or hereditary pathogenic mtDNA variants
S Reviews, systematic reviews, meta‐analyses, conference abstracts, pre‐clinical studies, editorials, commentaries Abbreviations: AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; ccf‐mtDNA, circulating cell‐free mtDNA; CN, copy number; mtDNA, mitochondrial DNA; MS, multiple sclerosis; PD, Parkinson's disease.

A priori defined inclusion and exclusion criteria according to the Population (P), Intervention (I), Comparison (C), Outcomes (O) and Study design (S) (PICOS) framework.

Main outcome : Subjects with a diagnosis of a neurodegenerative disease, including PD, AD, ALS, MS

Secondary outcome : Different clinical subtypes of each neurodegenerative disease

Studies on human subjects

Fully‐reported observational studies (prospective or retrospective) and cross‐sectional studies

Studies written in English

Measurement of mtDNA abundance and variant burden in other tissues/biosamples and postmortem ventricular cerebrospinal fluid

Assessment of mtDNA haplogroups or hereditary pathogenic mtDNA variants

Abbreviations: AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; ccf‐mtDNA, circulating cell‐free mtDNA; CN, copy number; mtDNA, mitochondrial DNA; MS, multiple sclerosis; PD, Parkinson's disease.

Study selection, data extraction and analysis

Titles and abstracts were screened by two independent reviewers (B.R. and A.I.) and selected for full‐text reading according to eligibility criteria. In case of disagreement on eligibility, a consensus was reached through discussion. The following data were extracted for eligible articles: first author name, year of publication, study design (cross‐sectional or longitudinal), number of subjects per group, exclusion criteria for subject enrolment, female percentage, mean age, disease duration, functional scale scores specific for each disease, biological source of analysis, technique of analysis, mtDNA parameter considered. Results were narratively exposed. Due to the heterogeneity of the included studies in terms of biological source and mtDNA parameters analysed, a meta‐analysis approach was not considered applicable.

Risk of bias assessment

The risk of bias and quality of each study was assessed through the Quality Assessment for Diagnostic Accuracy Studies (QUADAS‐2) criteria [ 35 ] by two independent reviewers (B.R. and A.I.). When at least one question per key domain received a negative answer, the final classification of that domain was “high risk of bias”; when at least one question per domain was considered unclearly answered, the final classification for that domain was “unclear”. When there was disagreement on a domain, a third reviewer (G.C.) was involved.

RESULTS

In total, 21,668 studies were retrieved from the database search. After deduplication, 14,636 studies were considered for title and abstract reading. Ninety‐five studies remained eligible for full‐text reading and 59 studies met the inclusion criteria (Figure  1 ).

PRISMA flow diagram of the articles selection process [ 33 ].

The majority of the studies analysed were found to be of high quality (Tables  S2 and S3 ). Nevertheless, there was a general absence of transparent reporting regarding the enrolment of participants, obscuring the ability to properly evaluate the risk of bias in patients' selection, which we deemed as unclear. Three studies were rated as high risk of bias due to case–control design [ 36 , 37 ] and enrolment through nationally televised appeal [ 38 ].

PARKINSON'S DISEASE

We retrieved 25 records addressing blood or CSF mtDNA measures in PD. Of these, nine were mainly focused on ccf‐mtDNA, nine on whole blood or leukocytes‐derived mtDNA and seven on mtDNA damage or methylation (Table  3 ). One study included both PD and AD patients [ 39 ].

TABLE 3 Demographic and clinical characteristics, methodology and main findings of included studies assessing mtDNA in patients with Parkinson's disease (PD). ccf‐mtDNA Study Design Sample size Exclusion criteria Female (%) Mean age (years) Disease duration (years) UPDRS‐III MMSE MoCA Source Method Main results Pyle A et al. 2015 [ 40 ] L (18 months)
56 PD
10 HC
NR
PD: 33.9
HC: 40.0

64.6 ± 9.1
60.6 ± 5.1

5.4 ± 4.9 months
‐

NR
‐

NR
‐

NR
‐
CSF qPCR
↓ in PD than HC both at baseline and 18 months
‐ROC curves for PD vs. HC discrimination:

MTND1 CN: AUC = 0.81

MTND4 CN: AUC = 0.84
No correlation with (i) age and sex; (ii) motor and cognitive scales
Podlesniy P et al. 2016 [ 41 ] CS
20 LRRK2‐PD
26 LRRK2‐NMC
31 iPD
21 HC
b


NR
55.0
38.4
32.2
47.6

64 ± 3
52 ± 3
58 ± 2
54 ± 3

7.4 ± 1.1
‐
4.0 ± 0.6
‐

29.8 ± 2.0
a


‐
NR
‐

NR
‐
NR

NR
‐
NR
CSF ddPCR
↑ in LRRK2‐PD vs. LRRK2‐NMC and iPD
↓ (non‐significant) in iPD vs. HC
ROC curve for LRRK2‐PD vs. iPD discrimination: SE = 70%, SP = 71%, AUC = 0.75
Chen YS et al. 2017 [ 44 ] CS
24 early onset PD
33 HC

PD and HC: cancer,
end‐stage renal disease, active infections, history of major trauma, autoimmune diseases, chronic inflammatory disorders

62.5
54.5

48.4 ± 6.5
48.6 ± 7.8

3.2 ± 3.0
‐

19.1 ± 13.6
‐

27.3 ± 2.3
28.3 ± 1.8
NR Plasma qPCR = between PD and HC Chen MH et al. 2017 [ 46 ] CS
29 PD
26 HC

PD: NR
HC: history of brain trauma,
substance abuse,
neurological or psychiatric diseases

31.0
26.9

61.5 ± 8.2
60.1 ± 7.7

NR
‐

27.0 ± 13.2
‐

NR
‐

NR
‐
Plasma qPCR ↑ in PD vs. HC Lowes H et al. 2020 [ 43 ] L (36 months)

Baseline:

291 PD (drug‐naïve)
132 HC
NR

Baseline:

34.0
38.0


Baseline:

61.2 (60.2‐62.3)
59.9 (58.0‐61.9)


Baseline:

6.8 months (6.0‐7.5)
‐


Baseline:

21.3 (20.2‐22.4)
‐
NR

Baseline:

27.1 (26.9‐27.4)
‐
CSF qPCR
= between PD and HC at baseline
↑ in PD with anxiety/depression and with insomnia at baseline
↓ (slightly) in PD vs. HC at FU
↓ in drug‐treated PD vs. drug‐naïve PD at FU


36 months (FU):

176 PD (90% drug‐treated)
87 HC


FU:

34.0
37.0


FU:

28.1 (26.2‐29.9)
‐


FU:

26.5 (26.1‐26.9)
‐

At baseline: elevated ccf‐mtDNA associated with cognitive impairment in PD (not confirmed at FU); no correlation with UPDRS (parts I‐III and total score)
At FU: negative correlation with LEDD
Borsche M et al. 2020 [ 28 ] CS
93 iPD
34 PRKN/PINK1 hom
24 PRKN/PINK1 het
26 PRKN/PINK1 unaffected carriers
156 HC

PD and unaffected
PRKN/PINK1 carriers: NR
HC: presence of PRKN or PINK1 variants

61.6 ± 11.9
51.3 ± 11.7
53.8 ± 13.0
50.7 ± 13.4
55.1 ± 10.9

8.4 ± 6.1
18.1 ± 8.8
8.9 ± 8.9
‐
‐

31.7 ± 15.1
a
32.2 ± 16.9
a


24.8 ± 14.7
a


‐
‐
NR NR Serum ddPCR ↑ in PRKN/PINK1 hom and PRKN/PINK1 het vs. iPD, PRKN/PINK1 unaffected carriers and HC Chen HL et al. 2021 [ 45 ] CS
25 PD‐NC
25 PD‐MCI
38 PDD
47 HC
NR
40.0
68.0
71.0
68.0

60.0 ± 10.0
63.8 ± 8.7
65.7 ± 8.0
61.5 ± 4.7

2.4 ± 1.9
3.0 ± 2.6
3.6 ± 4.2
‐

19.5 ± 13.1
24.7 ± 15.4
27.4 ± 14.4
‐

27.9 ± 1.7
27.0 ± 1.3
20.0 ± 4.5
‐
NR Plasma qPCR = between all groups Sharma A et al. 2021 [ 48 ] CS

Serum:

47 PD
40 HC

CSF:

12 PD
21 HC
NR

Serum:

36.1
50.0

CSF:

8.0
52.0
NR NR NR NR NR
Serum,
CSF (mtDNA levels)
PLTs (mtDNA methylation)

qPCR
bisulfite‐PCR pyrosequencing

↑ serum mtDNA (D‐loop and ATPase 6) levels in PD females vs. HC females (but = levels between PD males and HC males)
= CSF mtDNA levels between PD males and HC males (not evaluable in females due to low sample size)
mtDNA methylation = between PD and HC
Puigròs M et al. 2022 [ 42 ] CS

Discovery cohort:

20 LRRK2‐PD
28 iPD
26 NMC
17 NMNC
NR
55.0
29.0
50.0
53.0

64.2 ± 11.0
59.5 ± 10.0
52.6 ± 14.0
53.4 ± 16.0
NR
26.3 ± 11.0
a


NR
‐
‐
NR NR CSF ddPCR

Discovery cohort:

↑ in LRRK2‐PD vs. iPD and NMC
ccf‐mtDNA discriminated between iPD and NMNC with SE = 75%, SP = 70%; between iPD and LRRK2‐PD with SE = 80%, SP = 75%


Validation cohort:

21 iPD
12 HC

29.0
33.0

69.2 ± 7.0
68.5 ± 5.0

2.5 ± 11.0
a


‐

↓ mtDNA ND5/ND1 deletion ratio (i.e. higher levels of deletions) in iPD vs. all other groups


Validation cohort:

↓ mtDNA ND5/ND1 deletion ratio in iPD vs. HC
Whole blood/leukocytes‐derived mtDNA copy number Study Design Sample size Exclusion criteria Female (%) Mean age (years) Disease duration (years) UPDRS‐III MMSE MoCA Source Method Main results Gui YX et al. 2015 [ 49 ] CS
414 PD
231 HC
NR
42.9
47.1

61.2 ± 7.3
59.1 ± 10.2

5 (SD NR)
‐

NR
‐

NR
‐

NR
‐
Whole blood
qPCR

↓ of 40% in PD vs. HC
↓ in late (>50 y) vs. early onset group
↓ in POLG1‐mutated PD ( n  = 8) vs. POLG1‐wt PD
No correlation with motor symptoms.
Pyle A et al. 2015 [ 29 ] CS
363 PD
262 HC
NR
36.5
50.5

NR

NR
‐

NR
‐

NR
‐
NR Whole blood qPCR
↓ in PD vs. HC, independently from age and sex
↓ in PD smokers vs. PD non‐smokers
No correlation with motor or cognitive function
Pyle A et al. 2016 [ 47 ] CS

Blood:

360 PD
261 HC

CSF:

56 PD
10 HC
NR

Blood:

36.9
50.5

CSF:

33.9
40.0


Blood:

65.5 ± 9.7
67.8 ± 8.2

CSF:

64.6 ± 9.1
60.6 ± 5.1


Blood:

NR
‐
CSF:
5.4 ± 4.9 months
‐
NR NR NR
Whole‐blood cells,
CSF
qPCR CSF and blood mtDNA‐CN not associated with depression in PD or HC Gezen‐Ak D et al. 2020 [ 52 ] CS
107 PD
49 HC
PD and HC: diabetes mellitus
49
55

60.6 ± 9.6
57.4 ± 8.9

5.8 ± 4.2
‐
NR NR NR Blood leukocytes qPCR
= between PD (all) and HC
= between early (<50 years) and late (>50 years) onset PD subgroups
Chen SH et al. 2020 [ 50 ] L (range: 6‐64 months)
725 PD
744 HC

PD: secondary or atypical parkinsonism, focal lesions at brain CT or MRI
HC: any neurological sign or cognitive impairment

45.3
45.8

67.1 ± 11.1
66.2 ± 9.4

NR
‐

NR
‐

NR
‐
NR Whole blood qPCR
↓ in PD vs. HC
↓ in PD with higher LEDD
Negative correlation with age in HC (but not in PD)
During follow‐up average mtDNA‐CN decreased faster in PD than HC (PD: 0.38%/month, HC: 0.25%/month). LEDD at follow‐up was not correlated with mtDNA change over time.
Davis RL et al. 2020 [ 36 ] CS
37 EOPD
84 LOPD
103 HC

NR

32
40
54

52.4 ± 1.2
68.5 ± 0.8
61.4 ± 1.2

NR
‐

NR
‐

NR
‐

NR
‐
Whole blood qPCR
= between total PD and HC or between EOPD and LOPD
In total, PD group, mild correlation with age at onset (r = 0.220)
Yang SY et al. 2021 [ 39 ] L (UK Biobank: median FU time≈10 year)
Prevalent PD: 697
Incident PD: 965
NR NR NR NR NR NR NR Whole blood WES and genotyping data Lower mtDNA‐CN associated with increased risk for prevalent PD (OR = 0.90, CI 0.83‐0.9) and incident PD (HR = 0.92, CI 0.86‐0.98) Asghar M et al. 2022 [ 51 ] CS
100 PD
12 HC
NR
33
76

47‐97 (range)
54‐73 (range)

NR
‐

NR
‐

NR
‐

NR
‐
Whole blood qPCR
↓ in PD vs. HC
No correlation with LEDD, disease duration, MDS‐UPDRS‐III and H&Y stage
Müller‐Nedebock AC et al. 2022 [ 31 ] CS
72 PD
79 HC
NR
53
51

64 (IQR: 17)
77 (IQR: 11)

3
‐

NR
‐

NR
‐

NR
‐
Whole blood ddPCR ↑ in PD vs. HC (analysis not adjusted for age) mtDNA heteroplasmy/damage/methylation Study Design Sample size Exclusion criteria Female (%) Mean age (years) Disease duration (years) UPDRS‐III MoCA Source Method Parameter Main results Taravari A et al. 2014 [ 55 ] CS
18 PD
31 HC
NR
43.8
NR

52.7 ± 10.3
NR

NR
‐

NR
‐

NR
‐
Whole blood PCR
ΔmtDNA
4977 deletion
Present (hetero/homoplasmic) in 62.5% of patients vs. 25.8% of HC Casoli T et al. 2020 [ 56 ] CS
15 PD
15 HC

PD: other neurological diseases, secondary or atypical parkinsonism
HC: history of neurological disease, orthostatic hypotension, cognitive impairment

53.3
60.0

78.8 ± 6.0
80.8 ± 5.1

NR
‐

NR
‐

NR
‐
Whole blood MitoChip microarray
Ratio of expected allele (REA)
Heteroplasmy %

58 nucleotide positions differ between PD and HC, with 81% of REA values higher in HC than PD (i.e. higher frequency of non‐reference alleles in PD)
10 out of 58 nucleotide positions showed higher heteroplasmy % in PD than HC
Zaia A et al. 2020
c
[ 57 ] CS
15 PD
15 HC

PD: other neurological diseases, secondary or atypical parkinsonism
HC: history of neurological disease, orthostatic hypotension, cognitive impairment

53.3
60.0

78.8 ± 6.0
80.8 ± 5.1

NR
‐

NR
‐

NR
‐
Whole blood MitoChip microarray
Fractal lacunarity analysis
Heteroplasmy %

GenBank np 5713‐9713: β parameter (representative of mtDNA alterations) higher in PD than HC
No differences in heteroplasmy levels between PD and HC
Stoccoro A et al. 2021 [ 53 ] CS 30 PD PD: atypical parkinsonism 30.0 67.7 ± 10.4 52.8 ± 46.5 (months) NR NR Whole blood
qPCR,
methylation‐sensitive‐high‐res. melting
D‐loop methylation [DLM] DLM and mtDNA‐CN = between PD and HC 30 HC HC: NR 36.6 64.2 ± 14.0 ‐ ‐ ‐ Pyrosequencing mtDNA‐CN DLM is not correlated with dopaminergic treatment and disease duration Lüth T et al. 2021 [ 58 ] CS
5 PRKN‐PD
3 HC
NR
60.0
33.3

49.6
43.6

15.8
‐

NR
‐

NR
‐
Whole blood Nanopore sequencing and DNA methylation analysis mtDNA methylation ↓ in PRKN‐PD vs. HC Qi R et al. 2023 [ 54 ] CS

PBMCs:

53 iPD
10 HC


PBMCs:

Inflammatory or infectious diseases, drugs interfering with white blood cells; for HC only: participation in a clinical trial <6 months, cancer treatment <5 y, family history of PD


PBMCs:

60.6
36.3


PBMCs:

65.3 (37‐84)
63.9 (43‐78)


PBMCs:

5.9 (1‐19)
‐


PBMCs:

15.9
a


‐


PBMCs:

NR
PBMCs Buffy coat
mtDNA damage assay (Mito DNADX)
qPCR

mtDNA damage
mtDNA‐CN


PBMCs and buffy coat cohorts:

mtDNA damage ↑ in iPD PMBCs vs. HC (iPD vs. HC discrimination: AUC = 0.82 and 1.0, respectively)
mtDNA‐CN = between iPD and HC


Buffy c:

14 PD
6 HC


Buffy c:

Neurological or psychiatric conditions (other than PD), cardiovascular disease, hospitalization <3 months, MoCA <22, MRI contraindications, atypical parkinsonism, current participation in intervention trials


Buffy c:

14.2
33.3


Buffy c:

65.1 (53‐80)
64.8 (57‐ 69)


Buffy c:

NR
‐


Buffy c:

27.1
a


‐


Buffy c:

26.1
27.8


FBN cohort:

↑ mtDNA damage in LRRK2‐PD, LRRK2‐NMC and iPD vs. HC
mtDNA damage = between LRRK2‐PD, LRRK2‐NMC and iPD
↑ mtDNA damage in LRRK2‐NMC females vs. males


FBN:

30 iPD
28 LRRK2‐PD
17 LRRK2‐NMC
22 HC


FBN:

NR


FBN:

NR


FBN:

NR


FBN:

NR


FBN:

NR

mtDNA‐CN = between the four groups
mtDNA damage correlated with iPD age at diagnosis ( r  = 0.34)


AD:

10 AD
7 HC


AD:

Other neurological conditions, current smoker, cancer <5 years.


AD:

60
57


AD:

70 (58‐85)
68 (50‐83)


AD:

NR
‐


AD:

NR
‐


AD:

NR
‐


AD cohort

= mtDNA‐CN and mtDNA damage between AD and HC
Trinh J et al. 2023 [ 18 ] CS 59 PINK1‐PD NR 47 64.2 ± 15.2 25.4 NR NR Whole blood Short‐read sequencing mtDNA heteroplasmy ↑ of mtDNA heteroplasmic variants in monoallelic PINK1/PRKN‐PD (joint cohort) vs. PINK1/PRKN‐NMC (joint cohort) (AUC =0.83) 47 PINK1 het asymp. 47 62.1 ± 11.6 ‐ Nanopore sequencing Large scale deletions (ND4/ND1 ratio) ↑ of mtDNA heteroplasmic variants in PINK1/PRKN‐PD (joint cohort) vs. iPD 54 PRKN‐PD 46 59.7 ± 16.9 22.8 mtDNA transcription/replication initiation (7S DNA/ND1 ratio) ↑ of mtDNA heteroplasmic variants in biallelic PINK1/PRKN carriers vs. HC 79 PRKN het asymp. 52 47.9 ± 16.9 ‐ ↑ of mtDNA homoplasmic variants in PINK1/PRKN‐NMC (joint cohort) vs. iPD 67 iPD 40 74.3 ± 10.2 NR = mtDNA hetero‐ and homoplasmic variants burden in iPD vs. HC 90 HC 54 61.7 ± 18.3 ‐
↑ large mtDNA deletions in biallelic PINK1/PRKN carriers vs. monoallelic carriers and iPD
↓7S DNA: ND1 ratio in biallelic PINK1/PRKN carriers vs. monoallelic carriers and HC
↓7S DNA: ND1 ratio in iPD vs. HC

Note : Continuous variables are reported as mean ± SD or median (IQR). In the study by Davis RL et al. 2020 [36], mean age was reported as mean ± standard error of the mean. Abbreviations: AD, Alzheimer's disease; AUC, area under the curve; ccf‐mtDNA, circulating cell‐free mtDNA; CN, copy numer; CS, cross‐sectional; CSF, cerebrospinal fluid; ddPCR, droplet digital polymerase chain reaction; DLM, D‐loop methylation; DTI, diffusion tensor image; EOPD, early onset PD; FBN, Michael J. Fox Foundation Fox Bionet; FU, follow‐up; HC, healthy controls; hetero, heterozygous; homo, homozygous; H&Y, Hoehn and Yahr (scale); iPD, idiopathic PD; L, longitudinal; LOPD, late‐onset PD; LEDD, levodopa equivalent daily dose; LRRK2, carriers of G2019S mutation in LRRK2 gene; MDS‐UPDRS‐III, Movement Disorder Society‐Unified Parkinson's Disease Rating Scale–part III; MMSE, Mini‐Mental State Examination (scale); MoCA, Montreal Cognitive Assessment (scale); mtDNA, mitochondrial DNA; NMC, non‐manifesting carriers; NMNC, non‐manifesting non‐carriers; np, nucleotide position; NR, not reported; PBMC, peripheral blood mononuclear cell; PDD, PD with dementia; PD‐MCI, PD with mild cognitive impairment; PD‐NC, PD with normal cognition; PINK1 het asymp, asymptomatic carriers of monoallelic mutations in PINK1 ; PLTs, platelets; POLG‐wt, POLG gene wild type; PRKN het asymp, asymptomatic carriers of monoallelic mutations in PRKN ; PRKN/PINK1 het, PD patients carrying a monoallelic mutation in PRKN or PINK1 ; PRKN/PINK1 hom, PD patients carrying biallelic mutations in PRKN or PINK1 ; p‐tau, phospho‐tau; qPCR, quantitative (real time) polymerase chain reaction; SD, standard deviation; WES, whole exome sequencing; y, years.
a
MDS‐UPDRS‐III score according to the 2008 release.
b
Healthy controls non‐carriers of LRRK2 G2019S mutations.
c
This study was performed on mtDNA sequences derived from Casoli T et al. 2020 [ 56 ].

Demographic and clinical characteristics, methodology and main findings of included studies assessing mtDNA in patients with Parkinson's disease (PD).

56 PD

10 HC

PD: 33.9

HC: 40.0

64.6 ± 9.1

60.6 ± 5.1

5.4 ± 4.9 months

‐

NR

‐

NR

‐

NR

‐

↓ in PD than HC both at baseline and 18 months

‐ROC curves for PD vs. HC discrimination:

MTND1 CN: AUC = 0.81

MTND4 CN: AUC = 0.84

No correlation with (i) age and sex; (ii) motor and cognitive scales

20 LRRK2‐PD

26 LRRK2‐NMC

31 iPD

21 HC
b

55.0

38.4

32.2

47.6

64 ± 3

52 ± 3

58 ± 2

54 ± 3

7.4 ± 1.1

‐

4.0 ± 0.6

‐

29.8 ± 2.0
a

‐

NR

‐

NR

‐

NR

NR

‐

NR

↑ in LRRK2‐PD vs. LRRK2‐NMC and iPD

↓ (non‐significant) in iPD vs. HC

ROC curve for LRRK2‐PD vs. iPD discrimination: SE = 70%, SP = 71%, AUC = 0.75

24 early onset PD

33 HC

PD and HC: cancer,

end‐stage renal disease, active infections, history of major trauma, autoimmune diseases, chronic inflammatory disorders

62.5

54.5

48.4 ± 6.5

48.6 ± 7.8

3.2 ± 3.0

‐

19.1 ± 13.6

‐

27.3 ± 2.3

28.3 ± 1.8

29 PD

26 HC

PD: NR

HC: history of brain trauma,

substance abuse,

neurological or psychiatric diseases

31.0

26.9

61.5 ± 8.2

60.1 ± 7.7

NR

‐

27.0 ± 13.2

‐

NR

‐

NR

‐

Baseline:

291 PD (drug‐naïve)

132 HC

Baseline:

34.0

38.0

Baseline:

61.2 (60.2‐62.3)

59.9 (58.0‐61.9)

Baseline:

6.8 months (6.0‐7.5)

‐

Baseline:

21.3 (20.2‐22.4)

‐

Baseline:

27.1 (26.9‐27.4)

‐

= between PD and HC at baseline

↑ in PD with anxiety/depression and with insomnia at baseline

↓ (slightly) in PD vs. HC at FU

↓ in drug‐treated PD vs. drug‐naïve PD at FU

36 months (FU):

176 PD (90% drug‐treated)

87 HC

FU:

34.0

37.0

FU:

28.1 (26.2‐29.9)

‐

FU:

26.5 (26.1‐26.9)

‐

At baseline: elevated ccf‐mtDNA associated with cognitive impairment in PD (not confirmed at FU); no correlation with UPDRS (parts I‐III and total score)

At FU: negative correlation with LEDD

93 iPD

34 PRKN/PINK1 hom

24 PRKN/PINK1 het

26 PRKN/PINK1 unaffected carriers

156 HC

PD and unaffected

PRKN/PINK1 carriers: NR

HC: presence of PRKN or PINK1 variants

61.6 ± 11.9

51.3 ± 11.7

53.8 ± 13.0

50.7 ± 13.4

55.1 ± 10.9

8.4 ± 6.1

18.1 ± 8.8

8.9 ± 8.9

‐

‐

31.7 ± 15.1
a
32.2 ± 16.9
a

24.8 ± 14.7
a

‐

‐

25 PD‐NC

25 PD‐MCI

38 PDD

47 HC

40.0

68.0

71.0

68.0

60.0 ± 10.0

63.8 ± 8.7

65.7 ± 8.0

61.5 ± 4.7

2.4 ± 1.9

3.0 ± 2.6

3.6 ± 4.2

‐

19.5 ± 13.1

24.7 ± 15.4

27.4 ± 14.4

‐

27.9 ± 1.7

27.0 ± 1.3

20.0 ± 4.5

‐

Serum:

47 PD

40 HC

CSF:

12 PD

21 HC

Serum:

36.1

50.0

CSF:

8.0

52.0

Serum,

CSF (mtDNA levels)

PLTs (mtDNA methylation)

qPCR

bisulfite‐PCR pyrosequencing

↑ serum mtDNA (D‐loop and ATPase 6) levels in PD females vs. HC females (but = levels between PD males and HC males)

= CSF mtDNA levels between PD males and HC males (not evaluable in females due to low sample size)

mtDNA methylation = between PD and HC

Discovery cohort:

20 LRRK2‐PD

28 iPD

26 NMC

17 NMNC

55.0

29.0

50.0

53.0

64.2 ± 11.0

59.5 ± 10.0

52.6 ± 14.0

53.4 ± 16.0

26.3 ± 11.0
a

NR

‐

‐

Discovery cohort:

↑ in LRRK2‐PD vs. iPD and NMC

ccf‐mtDNA discriminated between iPD and NMNC with SE = 75%, SP = 70%; between iPD and LRRK2‐PD with SE = 80%, SP = 75%

Validation cohort:

21 iPD

12 HC

29.0

33.0

69.2 ± 7.0

68.5 ± 5.0

2.5 ± 11.0
a

‐

↓ mtDNA ND5/ND1 deletion ratio (i.e. higher levels of deletions) in iPD vs. all other groups

Validation cohort:

↓ mtDNA ND5/ND1 deletion ratio in iPD vs. HC

414 PD

231 HC

42.9

47.1

61.2 ± 7.3

59.1 ± 10.2

5 (SD NR)

‐

NR

‐

NR

‐

NR

‐

qPCR

↓ of 40% in PD vs. HC

↓ in late (>50 y) vs. early onset group

↓ in POLG1‐mutated PD ( n  = 8) vs. POLG1‐wt PD

No correlation with motor symptoms.

363 PD

262 HC

36.5

50.5

NR

NR

‐

NR

‐

NR

‐

↓ in PD vs. HC, independently from age and sex

↓ in PD smokers vs. PD non‐smokers

No correlation with motor or cognitive function

Blood:

360 PD

261 HC

CSF:

56 PD

10 HC

Blood:

36.9

50.5

CSF:

33.9

40.0

Blood:

65.5 ± 9.7

67.8 ± 8.2

CSF:

64.6 ± 9.1

60.6 ± 5.1

Blood:

NR

‐

CSF:

5.4 ± 4.9 months

‐

Whole‐blood cells,

CSF

107 PD

49 HC

49

55

60.6 ± 9.6

57.4 ± 8.9

5.8 ± 4.2

‐

= between PD (all) and HC

= between early (<50 years) and late (>50 years) onset PD subgroups

725 PD

744 HC

PD: secondary or atypical parkinsonism, focal lesions at brain CT or MRI

HC: any neurological sign or cognitive impairment

45.3

45.8

67.1 ± 11.1

66.2 ± 9.4

NR

‐

NR

‐

NR

‐

↓ in PD vs. HC

↓ in PD with higher LEDD

Negative correlation with age in HC (but not in PD)

During follow‐up average mtDNA‐CN decreased faster in PD than HC (PD: 0.38%/month, HC: 0.25%/month). LEDD at follow‐up was not correlated with mtDNA change over time.

37 EOPD

84 LOPD

103 HC

NR

32

40

54

52.4 ± 1.2

68.5 ± 0.8

61.4 ± 1.2

NR

‐

NR

‐

NR

‐

NR

‐

= between total PD and HC or between EOPD and LOPD

In total, PD group, mild correlation with age at onset (r = 0.220)

Prevalent PD: 697

Incident PD: 965

100 PD

12 HC

33

76

47‐97 (range)

54‐73 (range)

NR

‐

NR

‐

NR

‐

NR

‐

↓ in PD vs. HC

No correlation with LEDD, disease duration, MDS‐UPDRS‐III and H&Y stage

72 PD

79 HC

53

51

64 (IQR: 17)

77 (IQR: 11)

3

‐

NR

‐

NR

‐

NR

‐

18 PD

31 HC

43.8

NR

52.7 ± 10.3

NR

NR

‐

NR

‐

NR

‐

ΔmtDNA

4977 deletion

15 PD

15 HC

PD: other neurological diseases, secondary or atypical parkinsonism

HC: history of neurological disease, orthostatic hypotension, cognitive impairment

53.3

60.0

78.8 ± 6.0

80.8 ± 5.1

NR

‐

NR

‐

NR

‐

Ratio of expected allele (REA)

Heteroplasmy %

58 nucleotide positions differ between PD and HC, with 81% of REA values higher in HC than PD (i.e. higher frequency of non‐reference alleles in PD)

10 out of 58 nucleotide positions showed higher heteroplasmy % in PD than HC

15 PD

15 HC

PD: other neurological diseases, secondary or atypical parkinsonism

HC: history of neurological disease, orthostatic hypotension, cognitive impairment

53.3

60.0

78.8 ± 6.0

80.8 ± 5.1

NR

‐

NR

‐

NR

‐

Fractal lacunarity analysis

Heteroplasmy %

GenBank np 5713‐9713: β parameter (representative of mtDNA alterations) higher in PD than HC

No differences in heteroplasmy levels between PD and HC

qPCR,

methylation‐sensitive‐high‐res. melting

5 PRKN‐PD

3 HC

60.0

33.3

49.6

43.6

15.8

‐

NR

‐

NR

‐

PBMCs:

53 iPD

10 HC

PBMCs:

Inflammatory or infectious diseases, drugs interfering with white blood cells; for HC only: participation in a clinical trial <6 months, cancer treatment <5 y, family history of PD

PBMCs:

60.6

36.3

PBMCs:

65.3 (37‐84)

63.9 (43‐78)

PBMCs:

5.9 (1‐19)

‐

PBMCs:

15.9
a

‐

PBMCs:

NR

mtDNA damage assay (Mito DNADX)

qPCR

mtDNA damage

mtDNA‐CN

PBMCs and buffy coat cohorts:

mtDNA damage ↑ in iPD PMBCs vs. HC (iPD vs. HC discrimination: AUC = 0.82 and 1.0, respectively)

mtDNA‐CN = between iPD and HC

Buffy c:

14 PD

6 HC

Buffy c:

Neurological or psychiatric conditions (other than PD), cardiovascular disease, hospitalization <3 months, MoCA <22, MRI contraindications, atypical parkinsonism, current participation in intervention trials

Buffy c:

14.2

33.3

Buffy c:

65.1 (53‐80)

64.8 (57‐ 69)

Buffy c:

NR

‐

Buffy c:

27.1
a

‐

Buffy c:

26.1

27.8

FBN cohort:

↑ mtDNA damage in LRRK2‐PD, LRRK2‐NMC and iPD vs. HC

mtDNA damage = between LRRK2‐PD, LRRK2‐NMC and iPD

↑ mtDNA damage in LRRK2‐NMC females vs. males

FBN:

30 iPD

28 LRRK2‐PD

17 LRRK2‐NMC

22 HC

FBN:

NR

FBN:

NR

FBN:

NR

FBN:

NR

FBN:

NR

mtDNA‐CN = between the four groups

mtDNA damage correlated with iPD age at diagnosis ( r  = 0.34)

AD:

10 AD

7 HC

AD:

Other neurological conditions, current smoker, cancer <5 years.

AD:

60

57

AD:

70 (58‐85)

68 (50‐83)

AD:

NR

‐

AD:

NR

‐

AD:

NR

‐

AD cohort

= mtDNA‐CN and mtDNA damage between AD and HC

↑ large mtDNA deletions in biallelic PINK1/PRKN carriers vs. monoallelic carriers and iPD

↓7S DNA: ND1 ratio in biallelic PINK1/PRKN carriers vs. monoallelic carriers and HC

↓7S DNA: ND1 ratio in iPD vs. HC

Note : Continuous variables are reported as mean ± SD or median (IQR). In the study by Davis RL et al. 2020 [36], mean age was reported as mean ± standard error of the mean.

Abbreviations: AD, Alzheimer's disease; AUC, area under the curve; ccf‐mtDNA, circulating cell‐free mtDNA; CN, copy numer; CS, cross‐sectional; CSF, cerebrospinal fluid; ddPCR, droplet digital polymerase chain reaction; DLM, D‐loop methylation; DTI, diffusion tensor image; EOPD, early onset PD; FBN, Michael J. Fox Foundation Fox Bionet; FU, follow‐up; HC, healthy controls; hetero, heterozygous; homo, homozygous; H&Y, Hoehn and Yahr (scale); iPD, idiopathic PD; L, longitudinal; LOPD, late‐onset PD; LEDD, levodopa equivalent daily dose; LRRK2, carriers of G2019S mutation in LRRK2 gene; MDS‐UPDRS‐III, Movement Disorder Society‐Unified Parkinson's Disease Rating Scale–part III; MMSE, Mini‐Mental State Examination (scale); MoCA, Montreal Cognitive Assessment (scale); mtDNA, mitochondrial DNA; NMC, non‐manifesting carriers; NMNC, non‐manifesting non‐carriers; np, nucleotide position; NR, not reported; PBMC, peripheral blood mononuclear cell; PDD, PD with dementia; PD‐MCI, PD with mild cognitive impairment; PD‐NC, PD with normal cognition; PINK1 het asymp, asymptomatic carriers of monoallelic mutations in PINK1 ; PLTs, platelets; POLG‐wt, POLG gene wild type; PRKN het asymp, asymptomatic carriers of monoallelic mutations in PRKN ; PRKN/PINK1 het, PD patients carrying a monoallelic mutation in PRKN or PINK1 ; PRKN/PINK1 hom, PD patients carrying biallelic mutations in PRKN or PINK1 ; p‐tau, phospho‐tau; qPCR, quantitative (real time) polymerase chain reaction; SD, standard deviation; WES, whole exome sequencing; y, years.

MDS‐UPDRS‐III score according to the 2008 release.

Healthy controls non‐carriers of LRRK2 G2019S mutations.

This study was performed on mtDNA sequences derived from Casoli T et al. 2020 [ 56 ].

ccf‐mtDNA

Studies evaluating ccf‐mtDNA levels in idiopathic PD (iPD) patients gave conflicting results. Pyle et al. showed lower CSF mtDNA in early stage iPD than HC [ 40 ]. Other authors found a similar decreasing trend for CSF mtDNA in iPD compared to HC, but the difference did not reach statistical significance [ 41 , 42 ]. Additional studies showed similar CSF [ 43 ], plasma [ 44 , 45 ] and serum [ 28 ] levels of ccf‐mtDNA between iPD and HC, while one study found higher plasma ccf‐mtDNA levels in iPD than HC [ 46 ]. Lowes et al. revealed a longitudinal decrease of CSF mtDNA in iPD patients, but not in HC, over a 36‐month follow‐up. Given that at baseline the iPD patients were drug‐naïve, the authors attributed this observation to the negative correlation observed between mtDNA levels and levodopa equivalent daily dose (LEDD) [ 43 ]. The same study found increased baseline CSF mtDNA concentrations in PD patients with cognitive impairment compared to patients with normal cognition, which was not confirmed at follow‐up [ 43 ]. Other authors found no association between CSF or blood ccf‐mtDNA levels and cognitive, psychiatric or motor symptoms in PD [ 40 , 47 ]. Sharma et al. found a sex‐specific increase in serum ccf‐mtDNA levels in PD females compared to HC females [ 48 ]. However, another study found no effect of sex on CSF mtDNA levels [ 41 ].

Few studies evaluated ccf‐mtDNA levels in monogenic PD. Patients carrying the LRRK2 G2019S mutation (LRRK2‐PD) showed higher CSF mtDNA levels than LRRK2 G2019S non‐manifesting carriers (LRRK2‐NMC) and iPD [ 41 , 42 ]. Analogue findings were observed in the serum of PD patients carrying pathogenic variants in PRKN or PINK1 genes (PRKN/PINK1‐PD) compared to monoallelic unaffected carriers (PINK1/PRKN‐NMC), iPD and HC [ 28 ].

While one study found no correlation between CSF mtDNA and CSF tau, phosphorylated tau (p‐tau) or α‐synuclein levels in iPD [ 40 ], other authors showed a positive correlation of CSF mtDNA with CSF α‐synuclein and tau levels [ 41 ].

Whole blood and leukocytes‐derived mtDNA copy number

Most of the studies showed decreased whole‐blood mtDNA‐CN in PD compared to controls [ 29 , 49 , 50 , 51 ], independently of sex [ 29 ]. A UK Biobank‐based study found that lower mtDNA‐CN was associated with higher rates of prevalent and incident PD [ 39 ]. In contrast, some authors found unchanged [ 36 , 52 , 53 , 54 ] or increased [ 31 ] mtDNA‐CN in PD compared to HC. Gui et al. reported lower mtDNA‐CN in late‐onset compared to early onset PD patients [ 49 ], but this association was not confirmed in two subsequent studies [ 36 , 52 ]. One study found a negative correlation between LEDD and mtDNA‐CN [ 50 ], not confirmed in a later work [ 51 ]. There were no associations between mtDNA‐CN and PD motor or non‐motor phenotypes [ 29 , 47 , 49 , 51 ].

Few studies investigated whole‐blood mtDNA in monogenic PD. Qi et al. showed similar mtDNA‐CN between LRRK2‐PD, LRRK2‐NMC, iPD and HC groups [ 54 ]. Another study reported lower mtDNA‐CN in PD patients carrying single nucleotide polymorphisms or pathogenic variants in POLG1 [ 49 ]. No studies investigated the relationship between whole‐blood mtDNA and other biomarkers of neurodegeneration in PD.

mtDNA heteroplasmy, damage and methylation

Some studies reported higher levels of heteroplasmic variants [ 55 ], heteroplasmy percentage [ 56 ] or damage [ 54 , 57 ] in whole‐blood mtDNA of PD patients compared to HC. Stoccoro et al. found similar methylation levels in the mtDNA D‐loop region (a sequence involved in the regulation of mtDNA replication and transcription) between PD and HC, independently of sex [ 53 ]. One study showed reduced blood mtDNA CpG methylation in PRKN ‐PD compared to controls [ 58 ].

Only few works investigated the relationship of mtDNA damage and methylation levels with PD clinical features. One study found no correlation between disease duration and LEDD with D‐loop methylation [ 53 ]. Qi et al. found no correlation between blood mtDNA damage and demographic or clinical data, except for a positive correlation with age at PD diagnosis [ 54 ].

Two studies evaluated the blood mtDNA damage levels in monogenic PD. LRRK2‐PD, LRRK2 NMC and iPD showed higher mtDNA damage levels compared to HC, while there were no differences among LRRK2‐PD, LRRK2‐NMC and iPD groups. Interestingly, mtDNA damage was higher in LRRK2‐NMC females than males [ 54 ]. Trinh et al. showed higher number of mtDNA heteroplasmic variants in (i) PD patients carrying PRKN or PINK1 monoallelic mutations compared to asymptomatic monoallelic carriers; (ii) PD patients carrying monoallelic or biallelic PRKN / PINK1 mutations compared to iPD [ 18 ]. PD patients carrying biallelic PRKN/PINK1 mutations had more mtDNA large deletions than patients with monoallelic PRKN/PINK1 mutations or iPD [ 18 ].

ALZHEIMER'S DISEASE

We retrieved 22 records addressing blood or CSF mtDNA measures in AD. Of these, six were mainly focused on ccf‐mtDNA, six on whole blood or leukocyte‐derived mtDNA and 10 on mtDNA variants burden or methylation (Table  4 ).

TABLE 4 Demographic and clinical characteristics, methodology and main findings of included studies assessing mtDNA in patients with Alzheimer's disease (AD). ccf‐mtDNA Study Design Sample size Exclusion criteria Female (%) Mean age (years) Disease duration (years) MMSE CDR Source Method Main results Podlesniy P et al. 2013 [ 30 ] CS

Discovery cohort:

13 AD
15 FTD
6 PSEN1‐NMC
7 LAβ
10 C1
7 C2

Age >75 years
Signs of blood contamination, CSF total protein >0.7 mg/mL

61
NR
NR
NR
60
NR

64 ± 2
61 ± 2
35 ± 3
67 ± 3
62 ± 1
38 ± 3
NR NR NR CSF
qPCR
ddPCR


Discovery cohort:

↓ in AD and LAβ vs. C1
↑ in FTD vs. AD and LAβ
↓ in PSEN1‐NMC vs. C2
ccf‐mtDNA discriminates (i) AD vs. C1 (AUC = 0.99) and (ii) AD vs. FTD (AUC = 0.98)


Validation cohort:

17 AD
9 FTD
5 LAβ
19 C1
NR NR
66 ± 1
60 ± 2
67 ± 4
61 ± 1


Validation cohort:

Analogue findings of discovery cohort
APOE ε4 associated with low ccf‐mtDNA
Podlesniy P et al. 2016 [ 59 ] CS

Study cohort

13 non‐AD dementia
9 possible AD
22 sCJD
NR NR
63 ± 3
64 ± 3
62 ± 3
NR NR NR CSF ddPCR

Study cohort:

↓ in possible AD vs. sCJD and non‐AD dementia


Validation cohort

16 ND‐ctrl
29 sCJD
4 gCJD
19 AD
NR
70 ± 9
67 ± 7
64 ± 8
71 ± 9


Validation cohort:

↓ in AD vs. sCJD and ND‐ctrl


Combined cohort:

ROC curve AD vs. ND‐ctrl and non‐AD dementia: AUC = 0.83
ROC curve AD vs. sCJD: AUC = 0.78
Cervera‐Carles L et al. 2017 [ 62 ] CS
59 AD
20 pre‐clinical AD
43 MCI
140 HC
NR
52.5
60.0
67.4
60.7

72.5 ± 6.2
62.7 ± 6.1
71.7 ± 4.4
56.2 ± 4.6

NR
‐

22 ± 2.0
29 ± 1.0
27 ± 2.0
29 ± 1.0

NR
‐
CSF ddPCR
↑ in AD and MCI vs. HC
= between pre‐clinical AD and HC
mtDNA‐CN not affected by sex and age
ROC curve AD vs. HC: 0.715
Podlesniy P et al. 2020 [ 60 ]
30 spAD
16 rpAD
49 ND‐ctrl
NR
46.6
56.2
53.0

67 (60‐74)
68 (60‐80)
69 (66‐72)
NR NR NR CSF ddPCR
↓ in spAD vs. ND‐ctrl
= between rpAD and ND‐ctrl
ROC curve for ccf‐mtDNA/p‐tau total AD vs. ND‐ctrl: AUC = 0.79
Takousis P et al. 2022 [ 63 ] CS
12 AD
10 HC

AD: NR
HC: history of neurological/psychiatric disorders, SCD, abnormal MMSE or BDI score

50.0
20.0

75.4 ± 5.2
57.8 ± 17.2

NR
‐

NR

NR
‐
CSF
ddPCR,
qPCR
= between AD and HC Huang J et al. 2023 [ 61 ] CS 90 AD All: ongoing infections, inflammatory states 57.7 72.3 ± 5.9 19.2 ± 6.3 (months) NR NR Plasma qPCR (n° lesions/ 10 kb) Plasma: ↓ ccf‐mtDNA in AD vs. HC 90 HC 53.3 73.3 ± 5.6 ‐ ‐ PBMCs qPCR PBMCs: ↑ mtDNA damage in AD vs. HC Whole blood/leukocytes‐derived mtDNA copy number Study Design Sample size Exclusion criteria Female (%) Mean age (years) Disease duration (years) MMSE CDR Source Method Main results Rodríguez‐Santiago B et al. 2001 [ 67 ] CS 17 AD NR NR 59‐87 (range) NR NR NR Whole blood qPCR = between AD and HC 11 HC 61‐80 (range) ‐ ‐ Delbarba A et al. 2016 [ 64 ] CS

Spanish cohort

20 AD
24 MCI
30 HC
Otherneurological/psychiatric diseases, drug/alcohol abuse history, acute comorbidities
60.0
41.6
46.6

74 ± 7
73 ± 6
71 ± 8

26 ± 13 (months)
24 ± 14 (months)
‐

24 ± 3
27 ± 2
29 ± 1

1
0.5
0

Both cohorts: ↓ in AD and MCI vs. HC


Italian cohort

276 AD
70 MCI
248 HC
NR
64.1
37.1
52.8

78 ± 7
71 ± 8
75 ± 9

43 ± 31 (months)
30 ± 12 (months)
‐

15 ± 6
25 ± 4
29 ± 1

2 ± 1
0.5 ± 0.1
0
PBMCs qPCR Lunnon K et al. 2017 [ 68 ] CS
28 AD
31 MCI
28 HC
NR
60.7
58.0
57.1

80.3 ± 4.6
77.0 ± 6.9
77.5 ± 7.7

NR
‐

20.1 ± 4.6
27.3 ± 1.8
29.1 ± 1.0

1.1 ± 0.5
0.5 ± 0.0
0.0 ± 0.1
Whole blood qPCR = between AD, MCI and HC Lv X et al. 2019 [ 37 ] CS
82 AD
82 HC

AD: non‐AD dementia, hepatic/renal failure, chronic respiratory insufficiency, BD, schizophrenia, history of drug/alcohol abuse, other neurological disorders, age <55 years
HC: NR
NR NR
NR
‐

16.9 ± 4.8
28.5 ± 1.1

NR
‐
Whole blood qPCR
↓ mtDNA‐CN in AD vs. HC
↑ mtDNA deletions in AD vs. HC
Yang SY et al. 2021 [ 39 ] L (UK Biobank: median FU time≈10 years)
705 incident AD
368,714 controls
NR NR NR NR NR NR Whole blood WES and genotyping data mtDNA‐CN not associated with incident AD Liou CW et al. 2021 [ 65 ] CS
600 AD
601 HC
NR
58.8
56.7

76.4 ± 9.2
75.6 ± 8.4

NR
‐
NR
NR
‐
Whole blood qPCR
↓ in AD vs. HC
↑ in AchE‐treated AD vs. drug‐naïve AD
Chong M et al. 2022 [ 123 ] CS (IGADC‐based study)
17,008 AD
37,154 HC
NR NR NR NR NR NR Blood GWAS mtDNA‐CN estimate 1 SD in ↓ mtDNA‐CN associated with increased AD risk (OR = 1.41) mtDNA heteroplasmy/damage/methylation Study Design Sample size Exclusion criteria Female (%) Mean age (years) Disease duration (years) MMSE CDR Source Method Parameter Main results Fahy E et al. 1997 [ 69 ] CS
65 AD
73 controls (43 HC, 2 CBD, 2 Pick's disease, 16 PD, 10 non‐insulin‐dependent diabetes)
NR
NR
NR

74.7 ± 1.1
67 ± 1 years
NR NR NR Whole blood Multiplexed primer extension PCR Heteroplasmy %
↑ at 6 nucleotide sites in AD vs. controls
= heteroplasmy between PD and HC
Coon KD et al. 2006 [ 72 ] CS 19 AD NR 36.8 77.7 ± 4.4 NR NR NR Blood‐derived PLTs Array‐based mtDNA sequencing (MitoChip) n° of heteroplasmic variants = between AD and HC 18 HC 72.2 77.9 ± 4.4 ‐ ‐ Heteroplasmy % ↑ in HC (8.6%) vs. AD (7.9%) REA ↑ in AD (0.67) vs. HC (0.63) Wang PN et al. 2009 [ 70 ] CS
71 AD
84 aMCI
41 aging HC
40 young HC

All: renal insufficiency,
abnormal liver function, major surgery in the previous year, infections in the past 3 months

40.8
33.3
31.7
35.0

77.1 ± 7.1
76.6 ± 7.0
76.9 ± 7.0
41.5 ± 13.0

1.9
NR
‐
‐

20.4 ± 3.1
26.5 ± 2.0
28.2 ± 1.3
28.9 ± 1.0

1
0.5
0
0
Whole blood PCR + sequencing D‐loop heteroplasmy
↑ in AD and aMCI vs. control groups
AchEi treatment did not affect D‐loop heteroplasmy
Casoli T et al. 2014 [ 71 ] CS
18 AD
18 HC
NR
83.3
77.7

76.0 ± 1.2
74.1 ± 1.4

NR
‐

18.2 ± 1.0
28.0 ± 0.2

NR
‐
Whole blood mtDNA array (MitoChip) REA
↑ in HC vs. AD
270 nps discriminate between AD and HC
REA‐based cluster analysis correctly classified 80% of cases
Zaia A et al. 2017 [ 73 ] CS 14 AD NR 85.7 75.4 ± 5.1 NR 17.3 ± 3.4 NR Whole blood mtDNA array (MitoChip) Fractal lacunarity analysis β parameter lower in HC than AD (i.e. higher degree of mutations in HC) 14 HC 92.8 73.1 ± 5.1 ‐ 28.2 ± 0.8 ‐ n° heteroplasmic variants = n° heteroplasmic variants between AD and HC Stoccoro A et al. 2017 [ 76 ] CS
133 AD
130 HC

NR
MMSE <26, demented relatives

62.4
58.4

77.7 ± 7.0
78.9 ± 7.6

NR
‐
NR
1 or 2
0
Whole blood
Methylation‐sensitive‐high resolution
melting
D‐loop methylation [DLM] levels
↓ in AD vs. HC
No association between age and sex
Stoccoro A et al. 2022 [ 77 ] CS
18 esAD
70 asAD
14 MCI
105 HC

All: taking drugs, supplements or substances known to interfere with DNA methylation
HC: cognitive impairment, demented relatives

77.7
68.5
42.8
58.0

70.6 ± 6.4
72.4 ± 4.5
70.1 ± 6.3
72.3 ± 6.3

NR
‐

18.1 ± 5.9
<20
26.2 ± 4.0
NR

1
≥2
0.5
0
Whole blood
Methylation‐sensitive‐high resolution
melting
D‐loop methylation [DLM] levels
Total cohort: = no effect of sex
↑ in MCI vs. esAD, asAD and HC
↑ in HC vs. asAD
= between esAD and asAD
ROC for MCI vs. other groups discrimination: AUC = 0.77
Reid DM et al. 2022 [ 74 ] CS

NHW cohort:

64 AD
43 MCI
153 HC
Hachinski Ischemic Score >4, previous stroke, current cancer, other neurological/psychiatric diseases, acute inflammatory disorders, urinary infections
45.3
48.8
51.0

71.7 ± 1.0
71.3 ± 1.4
70.3 ± 1.1
NR
21.5 ± 1.4
27.6 ± 0.6
29.1 ± 0.1


CDR‐SB

5.3 ± 0.8
1.1 ± 0.2
0.0 ± 0.0
Buffy coat mtDNA amplification + NGS 8oxoG variant count ↑ trend in MAs AD (but not NHW) vs. MAs MCI and HC

MAs cohort:

40 AD
84 MCI
175 HC

60.0
47.6
56.6

73.3 ± 2.4
69.8 ± 1.6
67.6 ± 0.8

19.8 ± 1.8
24.9 ± 0.7
28.1 ± 0.2

5.7 ± 1.1
1.1 ± 0.1
0.0 ± 0.0

↑ in MAs females (all) vs. males (all)
Ding B et al. 2023 [ 78 ] CS 31 AD All: age <60 years, other causes of dementia or medical illnesses, psychosis, drug/alcohol abuse, medication use 45.1 80.3 ± 6.6 NR NR NR Plasma Whole‐genome bisulfite sequencing mtDNA methylation: 26 HC 50.0 77.3 ± 4.8 ‐ ‐ ‐average levels
↓ in AD vs. HC
‐D‐loop region ↓ in AD vs. HC ‐coefficient of variation ↑ in AD vs. HC Reid DM et al. 2023 [ 75 ] CS

NHW cohort:

64 AD
43 MCI
153 HC
Same as Reid et al. 2022
45.3
48.8
50.9

71.7 ± 1.0
71.3 ± 1.4
70.3 ± 1.1
NR
21.5 ± 1.4
27.6 ± 0.6
29.1 ± 0.1


CDR‐SB

5.7 ± 1.1
1.1 ± 0.2
0.0 ± 0. 0
Buffy coat, plasma mtDNA amplific. + NGS 8oxoG variant count

Buffy coat

“AD” and “female sex” associated with ↑ 8oxoG in MAs but not in NHWs


MAs cohort:

40 AD
84 MCI
175 HC

60.0
47.6
56.5

73.3 ± 2.4
69.8 ± 1.6
67.6 ± 0.8

19.8 ± 1.8
24.9 ± 1.1
28.1 ± 0.2

5.7 ± 1.1
1.1 ± 0.2
0.0 ± 0.0


Plasma ( ccf‐mtDNA )
= 8oxoG levels between AD and HC in both cohorts
No effect of sex on 8oxoG levels

Note : Continuous variables are reported as mean ± SD or median (IQR) or mean (range) (see the study by Podlesniy P et al. 2020 [ 55 ]). Abbreviations: 8‐OHdG, 8‐hydroxy‐2′‐deoxyguanosine; 8oxoG, 8‐oxo‐guanine; AD, Alzheimer's disease; aMCI, amnestic mild cognitive impairment; asAD, clinical dementia rating scale (≥2); AUC, area under the curve; BD, bipolar disorder; BDI, Beck Depression Inventory; C1, age‐matched control group including healthy subjects without cognitive deficits and normal CSF bio‐markers; C2, age‐matched control group including subjects without clinical, genetic or biochemical AD‐related alterations as a control for the PSEN1 group; CBD, corticobasal degeneration; ccf‐mtDNA, circulating cell‐free mtDNA; CDR, clinical dementia rating scale; CDR‐SB, clinical dementia rating scale sum of boxes; CN, copy numer; CS, cross‐sectional; CSF, cerebrospinal fluid; ddPCR, droplet digital polymerase chain reaction; esAD, early stage AD (clinical dementia rating scale = 1); FTD, frontotemporal dementia; gCJD, subjects carrying the missense mutation E200K in the prion protein gene causing familial Creutzfeldt‐Jakob disease; GWAS, genome‐wide association study; HC, healthy controls; IGADC, International Genomics of Alzheimer's Disease Consortium; L, longitudinal; LAβ, asymptomatic subjects at risk to develop AD who do not have cognitive deficits and only have low CSF Aβ1–42; MAs, Mexican‐americans; mtDNA, mitochondrial DNA; ND‐ctrl, subjects diagnosed with a neurological disorder without dementia; NGS, next‐generation sequencing; NHW, non‐hispanic white; NMC, non‐manifesting carriers; np, nucleotide position; PBMC, peripheral blood mononuclear cell; PD, Parkinson's disease; PLTs, platelets; PSEN1‐NMC, non‐manifesting carriers of a dominant pathogenic presenilin 1 mutation; p‐tau, phospho‐tau; qPCR, quantitative (real time) polymerase chain reaction; REA, ratio of expected allele; rpAD, rapidly progressive AD (MMSE decline >6 points/year); SCD, subjective cognitive decline; sCJD, sporadic Creutzfeldt‐Jakob disease; SD, standard deviation; spAD, slowly progressive AD (MMSE decline <6 points/year); t‐tau, total tau; WES, whole exome sequencing.

Demographic and clinical characteristics, methodology and main findings of included studies assessing mtDNA in patients with Alzheimer's disease (AD).

Discovery cohort:

13 AD

15 FTD

6 PSEN1‐NMC

7 LAβ

10 C1

7 C2

Age >75 years

Signs of blood contamination, CSF total protein >0.7 mg/mL

61

NR

NR

NR

60

NR

64 ± 2

61 ± 2

35 ± 3

67 ± 3

62 ± 1

38 ± 3

qPCR

ddPCR

Discovery cohort:

↓ in AD and LAβ vs. C1

↑ in FTD vs. AD and LAβ

↓ in PSEN1‐NMC vs. C2

ccf‐mtDNA discriminates (i) AD vs. C1 (AUC = 0.99) and (ii) AD vs. FTD (AUC = 0.98)

Validation cohort:

17 AD

9 FTD

5 LAβ

19 C1

66 ± 1

60 ± 2

67 ± 4

61 ± 1

Validation cohort:

Analogue findings of discovery cohort

APOE ε4 associated with low ccf‐mtDNA

Study cohort

13 non‐AD dementia

9 possible AD

22 sCJD

63 ± 3

64 ± 3

62 ± 3

Study cohort:

↓ in possible AD vs. sCJD and non‐AD dementia

Validation cohort

16 ND‐ctrl

29 sCJD

4 gCJD

19 AD

70 ± 9

67 ± 7

64 ± 8

71 ± 9

Validation cohort:

↓ in AD vs. sCJD and ND‐ctrl

Combined cohort:

ROC curve AD vs. ND‐ctrl and non‐AD dementia: AUC = 0.83

ROC curve AD vs. sCJD: AUC = 0.78

59 AD

20 pre‐clinical AD

43 MCI

140 HC

52.5

60.0

67.4

60.7

72.5 ± 6.2

62.7 ± 6.1

71.7 ± 4.4

56.2 ± 4.6

NR

‐

22 ± 2.0

29 ± 1.0

27 ± 2.0

29 ± 1.0

NR

‐

↑ in AD and MCI vs. HC

= between pre‐clinical AD and HC

mtDNA‐CN not affected by sex and age

ROC curve AD vs. HC: 0.715

30 spAD

16 rpAD

49 ND‐ctrl

46.6

56.2

53.0

67 (60‐74)

68 (60‐80)

69 (66‐72)

↓ in spAD vs. ND‐ctrl

= between rpAD and ND‐ctrl

ROC curve for ccf‐mtDNA/p‐tau total AD vs. ND‐ctrl: AUC = 0.79

12 AD

10 HC

AD: NR

HC: history of neurological/psychiatric disorders, SCD, abnormal MMSE or BDI score

50.0

20.0

75.4 ± 5.2

57.8 ± 17.2

NR

‐

NR

NR

‐

ddPCR,

qPCR

Spanish cohort

20 AD

24 MCI

30 HC

60.0

41.6

46.6

74 ± 7

73 ± 6

71 ± 8

26 ± 13 (months)

24 ± 14 (months)

‐

24 ± 3

27 ± 2

29 ± 1

1

0.5

0

Both cohorts: ↓ in AD and MCI vs. HC

Italian cohort

276 AD

70 MCI

248 HC

64.1

37.1

52.8

78 ± 7

71 ± 8

75 ± 9

43 ± 31 (months)

30 ± 12 (months)

‐

15 ± 6

25 ± 4

29 ± 1

2 ± 1

0.5 ± 0.1

0

28 AD

31 MCI

28 HC

60.7

58.0

57.1

80.3 ± 4.6

77.0 ± 6.9

77.5 ± 7.7

NR

‐

20.1 ± 4.6

27.3 ± 1.8

29.1 ± 1.0

1.1 ± 0.5

0.5 ± 0.0

0.0 ± 0.1

82 AD

82 HC

AD: non‐AD dementia, hepatic/renal failure, chronic respiratory insufficiency, BD, schizophrenia, history of drug/alcohol abuse, other neurological disorders, age <55 years

HC: NR

NR

‐

16.9 ± 4.8

28.5 ± 1.1

NR

‐

↓ mtDNA‐CN in AD vs. HC

↑ mtDNA deletions in AD vs. HC

705 incident AD

368,714 controls

600 AD

601 HC

58.8

56.7

76.4 ± 9.2

75.6 ± 8.4

NR

‐

NR

‐

↓ in AD vs. HC

↑ in AchE‐treated AD vs. drug‐naïve AD

17,008 AD

37,154 HC

65 AD

73 controls (43 HC, 2 CBD, 2 Pick's disease, 16 PD, 10 non‐insulin‐dependent diabetes)

NR

NR

74.7 ± 1.1

67 ± 1 years

↑ at 6 nucleotide sites in AD vs. controls

= heteroplasmy between PD and HC

71 AD

84 aMCI

41 aging HC

40 young HC

All: renal insufficiency,

abnormal liver function, major surgery in the previous year, infections in the past 3 months

40.8

33.3

31.7

35.0

77.1 ± 7.1

76.6 ± 7.0

76.9 ± 7.0

41.5 ± 13.0

1.9

NR

‐

‐

20.4 ± 3.1

26.5 ± 2.0

28.2 ± 1.3

28.9 ± 1.0

1

0.5

0

0

↑ in AD and aMCI vs. control groups

AchEi treatment did not affect D‐loop heteroplasmy

18 AD

18 HC

83.3

77.7

76.0 ± 1.2

74.1 ± 1.4

NR

‐

18.2 ± 1.0

28.0 ± 0.2

NR

‐

↑ in HC vs. AD

270 nps discriminate between AD and HC

REA‐based cluster analysis correctly classified 80% of cases

133 AD

130 HC

NR

MMSE <26, demented relatives

62.4

58.4

77.7 ± 7.0

78.9 ± 7.6

NR

‐

1 or 2

0

Methylation‐sensitive‐high resolution

melting

↓ in AD vs. HC

No association between age and sex

18 esAD

70 asAD

14 MCI

105 HC

All: taking drugs, supplements or substances known to interfere with DNA methylation

HC: cognitive impairment, demented relatives

77.7

68.5

42.8

58.0

70.6 ± 6.4

72.4 ± 4.5

70.1 ± 6.3

72.3 ± 6.3

NR

‐

18.1 ± 5.9

<20

26.2 ± 4.0

NR

1

≥2

0.5

0

Methylation‐sensitive‐high resolution

melting

Total cohort: = no effect of sex

↑ in MCI vs. esAD, asAD and HC

↑ in HC vs. asAD

= between esAD and asAD

ROC for MCI vs. other groups discrimination: AUC = 0.77

NHW cohort:

64 AD

43 MCI

153 HC

45.3

48.8

51.0

71.7 ± 1.0

71.3 ± 1.4

70.3 ± 1.1

21.5 ± 1.4

27.6 ± 0.6

29.1 ± 0.1

CDR‐SB

5.3 ± 0.8

1.1 ± 0.2

0.0 ± 0.0

MAs cohort:

40 AD

84 MCI

175 HC

60.0

47.6

56.6

73.3 ± 2.4

69.8 ± 1.6

67.6 ± 0.8

19.8 ± 1.8

24.9 ± 0.7

28.1 ± 0.2

5.7 ± 1.1

1.1 ± 0.1

0.0 ± 0.0

↑ in MAs females (all) vs. males (all)

↓ in AD vs. HC

NHW cohort:

64 AD

43 MCI

153 HC

45.3

48.8

50.9

71.7 ± 1.0

71.3 ± 1.4

70.3 ± 1.1

21.5 ± 1.4

27.6 ± 0.6

29.1 ± 0.1

CDR‐SB

5.7 ± 1.1

1.1 ± 0.2

0.0 ± 0. 0

Buffy coat

“AD” and “female sex” associated with ↑ 8oxoG in MAs but not in NHWs

MAs cohort:

40 AD

84 MCI

175 HC

60.0

47.6

56.5

73.3 ± 2.4

69.8 ± 1.6

67.6 ± 0.8

19.8 ± 1.8

24.9 ± 1.1

28.1 ± 0.2

5.7 ± 1.1

1.1 ± 0.2

0.0 ± 0.0

Plasma ( ccf‐mtDNA )

= 8oxoG levels between AD and HC in both cohorts

No effect of sex on 8oxoG levels

Note : Continuous variables are reported as mean ± SD or median (IQR) or mean (range) (see the study by Podlesniy P et al. 2020 [ 55 ]).

Abbreviations: 8‐OHdG, 8‐hydroxy‐2′‐deoxyguanosine; 8oxoG, 8‐oxo‐guanine; AD, Alzheimer's disease; aMCI, amnestic mild cognitive impairment; asAD, clinical dementia rating scale (≥2); AUC, area under the curve; BD, bipolar disorder; BDI, Beck Depression Inventory; C1, age‐matched control group including healthy subjects without cognitive deficits and normal CSF bio‐markers; C2, age‐matched control group including subjects without clinical, genetic or biochemical AD‐related alterations as a control for the PSEN1 group; CBD, corticobasal degeneration; ccf‐mtDNA, circulating cell‐free mtDNA; CDR, clinical dementia rating scale; CDR‐SB, clinical dementia rating scale sum of boxes; CN, copy numer; CS, cross‐sectional; CSF, cerebrospinal fluid; ddPCR, droplet digital polymerase chain reaction; esAD, early stage AD (clinical dementia rating scale = 1); FTD, frontotemporal dementia; gCJD, subjects carrying the missense mutation E200K in the prion protein gene causing familial Creutzfeldt‐Jakob disease; GWAS, genome‐wide association study; HC, healthy controls; IGADC, International Genomics of Alzheimer's Disease Consortium; L, longitudinal; LAβ, asymptomatic subjects at risk to develop AD who do not have cognitive deficits and only have low CSF Aβ1–42; MAs, Mexican‐americans; mtDNA, mitochondrial DNA; ND‐ctrl, subjects diagnosed with a neurological disorder without dementia; NGS, next‐generation sequencing; NHW, non‐hispanic white; NMC, non‐manifesting carriers; np, nucleotide position; PBMC, peripheral blood mononuclear cell; PD, Parkinson's disease; PLTs, platelets; PSEN1‐NMC, non‐manifesting carriers of a dominant pathogenic presenilin 1 mutation; p‐tau, phospho‐tau; qPCR, quantitative (real time) polymerase chain reaction; REA, ratio of expected allele; rpAD, rapidly progressive AD (MMSE decline >6 points/year); SCD, subjective cognitive decline; sCJD, sporadic Creutzfeldt‐Jakob disease; SD, standard deviation; spAD, slowly progressive AD (MMSE decline <6 points/year); t‐tau, total tau; WES, whole exome sequencing.

ccf‐mtDNA

The majority of studies showed reduced CSF [ 30 , 59 , 60 ] or plasma [ 61 ] ccf‐mtDNA levels in AD compared to controls. Conversely, other authors found increased [ 62 ] or unchanged [ 63 ] CSF ccf‐mtDNA in AD patients compared to HC. One study reported higher CSF ccf‐mtDNA in subjects with mild cognitive impairment (MCI) compared to HC [ 62 ]. Podlesnyi et al. reported decreased CSF ccf‐mtDNA levels in asymptomatic subjects having low CSF Aβ 1–42 levels and in presymptomatic patients carrying pathogenic PSEN1 mutations compared to age‐matched controls [ 30 ]. However, a subsequent study found no difference in CSF ccf‐mtDNA levels between pre‐clinical AD subjects and HC [ 62 ].

AD patients showed reduced CSF ccf‐mtDNA levels compared to patients affected by frontotemporal dementia [ 30 ] and Creutzfeldt‐Jakob disease [ 59 ]. These observations suggest that reduced CSF ccf‐mtDNA may be able to distinguish AD from other neurodegenerative dementias.

There were no sex‐specific differences in CSF ccf‐mtDNA levels within AD, MCI, pre‐clinical AD and control groups [ 30 , 62 ]. One work reported decreased CSF ccf‐mtDNA levels in slowly progressive (MMSE decline <6 points/year) AD, but not in rapidly progressive AD, compared to controls [ 60 ]. Two studies observed no correlation of CSF ccf‐mtDNA with AD‐related CSF biomarkers [ 59 , 62 ], while a single study showed positive and negative correlations of CSF ccf‐mtDNA with CSF Aβ 1‐42 and p‐tau levels, respectively [ 60 ].

Whole blood and leukocytes‐derived mtDNA copy number

Most studies reported decreased cell‐derived mtDNA‐CN in AD compared to HC [ 37 , 64 , 65 , 66 ], but in other works, blood mtDNA‐CN were unchanged between the two groups [ 39 , 67 , 68 ]. MCI patients showed reduced [ 64 ] or unaltered [ 68 ] mtDNA‐CN compared to HC.

Delbarba et al. reported a mild positive correlation between mtDNA‐CN and MMSE score in a joint cohort including AD, MCI and HC subjects [ 64 ]. Liou et al. showed (i) a decreasing trend of mtDNA‐CN with an increasing number of APOE4 alleles carried by AD patients; (ii) increased mtDNA‐CN in AD patients treated with acetylcholinesterase inhibitors compared to drug‐naïve patients [ 65 ].

mtDNA heteroplasmy, damage and methylation

The studies addressing mtDNA heteroplasmy in AD showed contrasting results. Some authors reported increased blood mtDNA heteroplasmy percentage or reduced ratio of expected allele (REA) (i.e. higher frequency of non‐reference alleles) in AD compared to controls [ 69 , 70 , 71 ]. However, other studies revealed an unchanged number of mtDNA heteroplasmic variants between AD and HC [ 72 , 73 ], and a reduced heteroplasmy percentage in AD compared to HC [ 72 ]. Wang et al. showed an unaltered D‐loop heteroplasmy rate in amnestic MCI compared to HC [ 70 ].

Blood mtDNA deletions and oxidative damage levels have been consistently reported to be elevated in AD compared to controls [ 37 , 61 ]. Two studies confirmed these findings in Mexican American (MAs) but not Non‐Hispanic White populations [ 74 , 75 ]. MAs females showed increased mtDNA damage compared to MAs males [ 74 , 75 ]. Interestingly, 8‐oxo‐guanine levels (an indicator of mtDNA oxidative stress) were increased in leukocytes‐derived mtDNA but not in plasma ccf‐mtDNA of MAs AD patients [ 75 ]. Two studies evaluating the relationship between APOE variants and mtDNA damage showed inconsistent results [ 74 , 75 ].

Several studies reported reduced mtDNA methylation in AD compared to controls [ 76 , 77 , 78 ]. Stoccoro et al. showed higher mtDNA methylation levels in (i) MCI patients compared to AD patients and HC; (ii) HC compared to advanced stage AD, but not early stage AD [ 77 ]. These data suggest that mtDNA methylation may be abnormally increased in the prodromal (MCI) AD stages, and then decrease with the progression of the disease. D‐loop methylation correlated negatively with CSF p‐tau levels, but not with CSF total tau, Aβ 1‐42 or MMSE score [ 77 ].

AMYOTROPHIC LATERAL SCLEROSIS (ALS)

We retrieved 4 records addressing whole‐blood mtDNA measures in ALS, of which 1 focused on mtDNA‐CN, 2 on mtDNA‐CN and methylation and 1 on mtDNA‐CN and heteroplasmy. No studies were focused on CSF or ccf‐mtDNA (Table  5 ).

TABLE 5 Demographic and clinical characteristics, methodology and main findings of included studies assessing mtDNA in patients with amyotrophic lateral sclerosis (ALS). Study Design Sample size Exclusion criteria Female (%) Mean age (years) Disease duration (years) ALSFRS‐R Source Method Parameter Main results Ehinger JK et al. 2015 [ 79 ] CS
24 ALS
21 HC
NR
37.5
71.4

64.9 ± 12.3
64.6 ± 11.6

NR
‐

NR
‐

PLTs,
PBMCs
qPCR mtDNA‐CN ↑ in PLTs from ALS vs. HC Stoccoro A et al. 2018 [ 80 ] CS
54 fALS
23 pre‐fALS
32 non‐carriers
NR
50
60.7
50

56.4 ± 12.3
45 ± 16.6
55.3 ± 13.6

NR
‐

NR
‐
Whole blood
qPCR,
MS‐HRM assay

mtDNA‐CN,
D‐loop methylation [DLM]

Negative correlation between DLM and mtDNA‐CN (↑ mtDNA‐CN in subjects with de‐methylated vs. methylated D‐loop region)
↑ mtDNA‐CN in fALS (SOD1 and C9‐mutated) vs. non‐carriers
↓ DLM in SOD1‐mutated vs. non‐carriers
Stoccoro A et al. 2020 [ 81 ] CS
63 ALS (27 fALS)
51 HC
NR
47.6
47.1

64.2 ± 11.1
67.0 ± 13.5

NR
‐

NR
‐
WBCs qPCR, bisulfite pyrosequencing
mtDNA‐CN,
D‐loop methylation [DLM]

Negative correlation between D‐loop methylation and mtDNA‐CN
In ALS vs. HC:
↓ DLM (sALS and SOD1‐ALS)
↑ mtDNA‐CN (SOD1‐ALS) vs. HC
Only in HC: DLM influenced by age (neg.corr) and sex (↑ in M); mtDNA‐CN influenced by sex (↑ in F)
Brockmann SJ et al. 2023 [ 82 ] CS

Cohort 1:

23 m‐ALS
25 nm‐ALS
49 HC
NR
Cohort 1:
39.2
42.3
44.9

Cohort 1:
55.9 ± 11.1
58.1 ± 10.4
57.7 ± 11.2

Cohort 1:
3.5 ( n  = 26)
‐

Cohort 1:
NR
‐
Whole blood, WBCs, PLTs
qPCR
Resequencing microarray

mtDNA‐CN
Homoplasmy and heteroplasmy levels

= between ALS and HC
↑ in m‐ALS vs. nm‐ALS
↑ homoplasmic mutations in ND5 in whole blood from (bulbar) m‐ALS vs. nm‐ALS
↑ heteroplasmic mutations in PLTs from m‐ALS vs. nm‐ALS (and HC for D‐loop and ATP8)


Cohort 2:

6 m‐ALS
16 nm‐ALS
22 HC

Cohort 2:
33.4
43.7
40.9

Cohort 2:
61.8 ± 9.8
60.5 ± 10.4
61.4 ± 10.6

Cohort 2:
4.6 ( n  = 5)
‐

Cohort 2:
NR
‐

Note : Continuous variables are reported as mean ± SD or median (IQR). Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS‐R, ALS functional rating scale revised; CN, copy number; CS, cross‐sectional; CSF, cerebrospinal fluid; ddPCR, droplet digital polymerase chain reaction; DLM, D‐loop methylation; fALS, familial ALS; HC, healthy controls; MS‐HRM, methylation‐sensitive‐high resolution melting; m‐ALS, maternally inherited ALS; MS‐HRM, methylation‐sensitive‐high resolution melting; mtDNA, mitochondrial DNA; nm‐ALS, non‐maternally inherited ALS; NR, not reported; PBMCs, peripheral blood mononuclear cells; PLTs, platelets; pre‐fALS, presymptomatic familial ALS; qPCR, quantitative (real time) polymerase chain reaction; sALS, sporadic ALS; T2DM, type 2 diabetes mellitus; WBCs, white blood cells.

Demographic and clinical characteristics, methodology and main findings of included studies assessing mtDNA in patients with amyotrophic lateral sclerosis (ALS).

24 ALS

21 HC

37.5

71.4

64.9 ± 12.3

64.6 ± 11.6

NR

‐

NR

‐

PLTs,

PBMCs

54 fALS

23 pre‐fALS

32 non‐carriers

50

60.7

50

56.4 ± 12.3

45 ± 16.6

55.3 ± 13.6

NR

‐

NR

‐

qPCR,

MS‐HRM assay

mtDNA‐CN,

D‐loop methylation [DLM]

Negative correlation between DLM and mtDNA‐CN (↑ mtDNA‐CN in subjects with de‐methylated vs. methylated D‐loop region)

↑ mtDNA‐CN in fALS (SOD1 and C9‐mutated) vs. non‐carriers

↓ DLM in SOD1‐mutated vs. non‐carriers

63 ALS (27 fALS)

51 HC

47.6

47.1

64.2 ± 11.1

67.0 ± 13.5

NR

‐

NR

‐

mtDNA‐CN,

D‐loop methylation [DLM]

Negative correlation between D‐loop methylation and mtDNA‐CN

In ALS vs. HC:

↓ DLM (sALS and SOD1‐ALS)

↑ mtDNA‐CN (SOD1‐ALS) vs. HC

Only in HC: DLM influenced by age (neg.corr) and sex (↑ in M); mtDNA‐CN influenced by sex (↑ in F)

Cohort 1:

23 m‐ALS

25 nm‐ALS

49 HC

Cohort 1:

39.2

42.3

44.9

Cohort 1:

55.9 ± 11.1

58.1 ± 10.4

57.7 ± 11.2

Cohort 1:

3.5 ( n  = 26)

‐

Cohort 1:

NR

‐

qPCR

Resequencing microarray

mtDNA‐CN

Homoplasmy and heteroplasmy levels

= between ALS and HC

↑ in m‐ALS vs. nm‐ALS

↑ homoplasmic mutations in ND5 in whole blood from (bulbar) m‐ALS vs. nm‐ALS

↑ heteroplasmic mutations in PLTs from m‐ALS vs. nm‐ALS (and HC for D‐loop and ATP8)

Cohort 2:

6 m‐ALS

16 nm‐ALS

22 HC

Cohort 2:

33.4

43.7

40.9

Cohort 2:

61.8 ± 9.8

60.5 ± 10.4

61.4 ± 10.6

Cohort 2:

4.6 ( n  = 5)

‐

Cohort 2:

NR

‐

Note : Continuous variables are reported as mean ± SD or median (IQR).

Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS‐R, ALS functional rating scale revised; CN, copy number; CS, cross‐sectional; CSF, cerebrospinal fluid; ddPCR, droplet digital polymerase chain reaction; DLM, D‐loop methylation; fALS, familial ALS; HC, healthy controls; MS‐HRM, methylation‐sensitive‐high resolution melting; m‐ALS, maternally inherited ALS; MS‐HRM, methylation‐sensitive‐high resolution melting; mtDNA, mitochondrial DNA; nm‐ALS, non‐maternally inherited ALS; NR, not reported; PBMCs, peripheral blood mononuclear cells; PLTs, platelets; pre‐fALS, presymptomatic familial ALS; qPCR, quantitative (real time) polymerase chain reaction; sALS, sporadic ALS; T2DM, type 2 diabetes mellitus; WBCs, white blood cells.

mtDNA‐CN was increased in ALS patients compared to HC in three studies analysing platelets [ 79 ] and lymphocytes [ 80 , 81 ] as cellular source. In another work, higher blood mtDNA‐CN has been found in familiar cases of ALS with presumed maternal origin compared to non‐maternal pedigrees [ 82 ]; however, no differences were found between ALS and controls. Brockmann et al. investigated the association between ALS and mtDNA point mutations. Maternal familiar ALS cases showed higher levels of (i) whole‐blood mtDNA homoplasmic mutations in the MT‐ND5 gene (specifically in patients with bulbar phenotype); (ii) heteroplasmic mutations in other mtDNA “mutational hotspots” in platelets than non‐maternal cases. No correlation was found between the number of ND5 mutations and ALS functional rating scale revised (ALSFRS‐Rdecline per month, age at onset or disease duration [ 82 ].

Lower levels of D‐loop methylation were found in sporadic and SOD1‐ALS patients (but not in patients carrying pathogenic variants in C9orf72, FUS or TARDBP ) compared to controls [ 80 , 81 ]. In controls, D‐loop methylation was influenced by age and sex whereas an inverse correlation between D‐loop methylation levels and mtDNA‐CN was observed in both controls and ALS patients [ 80 , 81 ].

MULTIPLE SCLEROSIS (MS)

The focus of our work was neurodegeneration, which mainly characterises the progressive stages of MS (referred to as progressive Multiple Sclerosis, PMS) [ 13 ]. Nevertheless, we decided to also include articles addressing relapsing‐remitting MS (RRMS) for two reasons: (i) most manuscripts evaluated all phenotypes of MS, with only a few specifically dedicated to PMS; (ii) to have a complete overview, as the “immunological” and “neurodegenerative” processes overlap in a continuum since the early phases of the disease [ 13 ]. We retrieved a total of eight records (three on both RRMS and PMS, one on PMS only and four on RRMS only). Of these, three studies investigated CSF ccf‐mtDNA and five analysed whole blood or leukocytes mtDNA‐CN (Table  6 ).

TABLE 6 Demographic and clinical characteristics, methodology and main findings of included studies assessing mtDNA in patients with multiple sclerosis (MS). Study Design Sample size Exclusion criteria Female (%) Mean age (years) Disease duration (years) EDSS Source Method Parameter Main results Souren N et al. 2016 [ 38 ] CS 49 MZ twins pairs NR 75.5 42.7 ± 11.1 13.6 ± 10.7 NR Whole blood, buccal swab qPCR and LR‐PCR
mtDNA‐CN
Heteroplasmy

= mtDNA‐CN in non‐affected and MS‐affected cotwins
Similar levels of heteroplasmy in cotwins
Varhaug KN et al. 2017 [ 83 ] CS
21 RRMS
23 Controls

MS: no previous/actual immunotherapy
Controls: without inflammatory and neurodegenerative diseases, with normal CSF white cell count and normal MRI

76
70

41.9 ± 14.1
42.1 ± 16.7

NR
‐

NR
‐
CSF qPCR
ccf‐mtDNA

↑ in RRMS vs. other disease controls
Negative correlation with disease duration
Leurs CE et al. 2018 [ 84 ]
CS
L (6‐12 months) for fingolimod‐treated patients


Cohort 1:

50 RRMS
27 SPMS
13 PPMS
Cohort 1: NA
Cohort 1:
62
44.4
38.5

Cohort 1:
41.4 ± 9.6
49.6 ± 7.6
50.4 ± 5.3

Cohort 1:
6.5 (2.9‐13.7)
19.3 ± 8.7
10.2 (3.8‐19.7)

Cohort 1:
3.0 (2.5‐4)
6.0 (4‐7)
4.0 (3.5‐6)
CSF ddPCR ccf‐mtDNA

Cohort 1:

↑ in progressive MS [PMS] vs. NIND
↑ (trend, not significant) in PMS vs. RRMS

23 NIND
7 IND

56.5
42.9

47.5 ± 15.1
43.3 ± 15.1

1.14 (0.3–2.8)
0.07 (0.0–2.8)

‐
‐


Cohort 2:

42 RRMS ( n  = 23 treated with Fingolimod)
Cohort 2: significant concomitant diseases (i.e. infections), corticosteroids within 3 months of sampling
Cohort 2:
71.4

Cohort 2:
42.4 ± 8.1
(treated)
32.4 ± 8.1
(untreated)

Cohort 2:
10.3 ± 6.1
(treated)
5.89 ± 4.3
(untreated)

Cohort 2:
3.0 (2‐3.5)
(treated)
2.0 (1.5‐3.0)
(untreated)


Cohort 2:

↓ in RRMS patients treated at follow‐up (6‐12 months)
= between RRMS, OND and HC

20 OND
5 HC

65
40

34.15 ± 11
29.8 ± 2.9

‐
‐

‐
‐
Fissolo N et al. 2019 [ 85 ] L
51 RRMS
38 SPMS
36 PPMS
31 CIS
NR
62.7
57.9
61.1
78.7
[all 60.8]

36.3 ± 9.8
51.3 ± 10.1
49.3 ± 10.43
6.9 ± 11.5
[all 4.7 ± 12.2]

5.3 ± 6.3
15.4 ± 10.9
5.0 ± 4.4
‐
[all 8.3 ± 8.9]

2.0 (1.5‐3)
5.5 (4‐6.5)
3.0 (4.8‐6)
‐
[all 3.0 (2‐5.7)]
CSF ddPCR
ccf‐mtDNA

↑ in all diseases vs. HC
= between RRMS, SPMS and PPMS
= between CIS who remained so and those who converted to MS

41 HC
20 NIND
20 IND

48.8
45
35

53.3 ± 13.7
68 ± 9.5
49.7 ± 17.5

‐
‐
‐

‐
‐
‐
Nasi M et al. 2020 [ 88 ] CS
38 SPMS
35 PPMS
42 HC

MS: concomitant infections, immunosuppr. or corticosteroid therapy
HC: autoimmune diseases, immunosuppr. or corticosteroid therapy

65.8
65.7
57.1

58.5 ± 1.1
58.7 ± 1.1
53 ± 1.6

24.3 ± 1.5
17.1 ± 1.6
‐

6.5 ± 0.2
5.4 ± 0.3
‐
Whole blood qPCR
mtDNA‐CN
↑ in SPMS vs. PPMS Al‐Kafaji G et al. 2020 [ 86 ] CS
60 RRMS
64 HC

MS: NR
HC: inflammatory and neurological disorders or active infections

76.7
73.4

30.4 ± 8.9
36.7 ± 12.2

6.3 ± 4.5
‐

4.8 ± 7.1
‐
Whole blood qPCR mtDNA‐CN
↓ in RRMS vs. HC
↓ in patients with longer (>10 y) disease duration
López‐Armas GDC et al. 2023 [ 89 ] CS
50 mild/mod
25 severe RRMS
10 HC

MS: cancer,
diabetes, hypertension, immunological diseases
HC: NR

66
68
NR

37.7 ± 11.4
43 ± 11.1
40.6 ± 8.7

7.8 ± 5.1
10.2 ± 6.9
‐

1.9 ± 0.9
4.9 ± 1.1
‐
WBCs qPCR
mtDNA‐CN
LTL
Positive correlation with LTL in patients with mild–moderate RRMS Sedky RM et al. 2023 [ 87 ] CS/L 25 RRMS (during remission and relapse) MS: autoimmune/neurodegenerative diseases, malignancy, T2DM 52 33 (26‐41) NR
3.5 (3–5.2) in disease dur. <6 years
4 (2–5) in disease dur. >6 years
Whole blood qPCR mtDNA‐CN
↓ in remission vs. relapse
↓ in RRMS during remission vs. HC
= between RRMS during relapse and HC
25 HC HC: inflammatory and neurological disorders or active infections 44 30 (24‐35) ‐ ‐
Note : Continuous variables are reported as mean ± SD or median (IQR). Abbreviations: ccf‐mtDNA, circulating cell‐free mtDNA; CIS, clinically isolated syndrome; CN, mitochondrial DNA copy number; CS, cross‐sectional; CSF, cerebrospinal fluid; ddPCR, digital droplet polymerase chain reaction; EDSS, Expanded Disability Status Scale; HC, healthy controls; IND, inflammatory neurological diseases; indels, insertions/deletions; L, longitudinal; LR‐PCR, long‐range polymerase chain reaction; LTL, leukocyte telomere length; mtDNA, mitochondrial DNA; MZ, monozygotic; NR, not reported; NF‐L, neurofilament light chain; NIND, non‐inflammatory neurological diseases; OND, other neurological diseases; qPCR, quantitative (real time) polymerase chain reaction; RRMS, relapsing‐remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; PPMS, primary progressive multiple sclerosis; T2DM, type 2 diabetes mellitus; WBCs, white blood cells; y, years.

Demographic and clinical characteristics, methodology and main findings of included studies assessing mtDNA in patients with multiple sclerosis (MS).

mtDNA‐CN

Heteroplasmy

= mtDNA‐CN in non‐affected and MS‐affected cotwins

Similar levels of heteroplasmy in cotwins

21 RRMS

23 Controls

MS: no previous/actual immunotherapy

Controls: without inflammatory and neurodegenerative diseases, with normal CSF white cell count and normal MRI

76

70

41.9 ± 14.1

42.1 ± 16.7

NR

‐

NR

‐

ccf‐mtDNA

↑ in RRMS vs. other disease controls

Negative correlation with disease duration

CS

L (6‐12 months) for fingolimod‐treated patients

Cohort 1:

50 RRMS

27 SPMS

13 PPMS

Cohort 1:

62

44.4

38.5

Cohort 1:

41.4 ± 9.6

49.6 ± 7.6

50.4 ± 5.3

Cohort 1:

6.5 (2.9‐13.7)

19.3 ± 8.7

10.2 (3.8‐19.7)

Cohort 1:

3.0 (2.5‐4)

6.0 (4‐7)

4.0 (3.5‐6)

Cohort 1:

↑ in progressive MS [PMS] vs. NIND

↑ (trend, not significant) in PMS vs. RRMS

23 NIND

7 IND

56.5

42.9

47.5 ± 15.1

43.3 ± 15.1

1.14 (0.3–2.8)

0.07 (0.0–2.8)

‐

‐

Cohort 2:

42 RRMS ( n  = 23 treated with Fingolimod)

Cohort 2:

71.4

Cohort 2:

42.4 ± 8.1

(treated)

32.4 ± 8.1

(untreated)

Cohort 2:

10.3 ± 6.1

(treated)

5.89 ± 4.3

(untreated)

Cohort 2:

3.0 (2‐3.5)

(treated)

2.0 (1.5‐3.0)

(untreated)

Cohort 2:

↓ in RRMS patients treated at follow‐up (6‐12 months)

= between RRMS, OND and HC

20 OND

5 HC

65

40

34.15 ± 11

29.8 ± 2.9

‐

‐

‐

‐

51 RRMS

38 SPMS

36 PPMS

31 CIS

62.7

57.9

61.1

78.7

[all 60.8]

36.3 ± 9.8

51.3 ± 10.1

49.3 ± 10.43

6.9 ± 11.5

[all 4.7 ± 12.2]

5.3 ± 6.3

15.4 ± 10.9

5.0 ± 4.4

‐

[all 8.3 ± 8.9]

2.0 (1.5‐3)

5.5 (4‐6.5)

3.0 (4.8‐6)

‐

[all 3.0 (2‐5.7)]

ccf‐mtDNA

↑ in all diseases vs. HC

= between RRMS, SPMS and PPMS

= between CIS who remained so and those who converted to MS

41 HC

20 NIND

20 IND

48.8

45

35

53.3 ± 13.7

68 ± 9.5

49.7 ± 17.5

‐

‐

‐

‐

‐

‐

38 SPMS

35 PPMS

42 HC

MS: concomitant infections, immunosuppr. or corticosteroid therapy

HC: autoimmune diseases, immunosuppr. or corticosteroid therapy

65.8

65.7

57.1

58.5 ± 1.1

58.7 ± 1.1

53 ± 1.6

24.3 ± 1.5

17.1 ± 1.6

‐

6.5 ± 0.2

5.4 ± 0.3

‐

mtDNA‐CN

60 RRMS

64 HC

MS: NR

HC: inflammatory and neurological disorders or active infections

76.7

73.4

30.4 ± 8.9

36.7 ± 12.2

6.3 ± 4.5

‐

4.8 ± 7.1

‐

↓ in RRMS vs. HC

↓ in patients with longer (>10 y) disease duration

50 mild/mod

25 severe RRMS

10 HC

MS: cancer,

diabetes, hypertension, immunological diseases

HC: NR

66

68

NR

37.7 ± 11.4

43 ± 11.1

40.6 ± 8.7

7.8 ± 5.1

10.2 ± 6.9

‐

1.9 ± 0.9

4.9 ± 1.1

‐

mtDNA‐CN

LTL

3.5 (3–5.2) in disease dur. <6 years

4 (2–5) in disease dur. >6 years

↓ in remission vs. relapse

↓ in RRMS during remission vs. HC

= between RRMS during relapse and HC

Note : Continuous variables are reported as mean ± SD or median (IQR).

Abbreviations: ccf‐mtDNA, circulating cell‐free mtDNA; CIS, clinically isolated syndrome; CN, mitochondrial DNA copy number; CS, cross‐sectional; CSF, cerebrospinal fluid; ddPCR, digital droplet polymerase chain reaction; EDSS, Expanded Disability Status Scale; HC, healthy controls; IND, inflammatory neurological diseases; indels, insertions/deletions; L, longitudinal; LR‐PCR, long‐range polymerase chain reaction; LTL, leukocyte telomere length; mtDNA, mitochondrial DNA; MZ, monozygotic; NR, not reported; NF‐L, neurofilament light chain; NIND, non‐inflammatory neurological diseases; OND, other neurological diseases; qPCR, quantitative (real time) polymerase chain reaction; RRMS, relapsing‐remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; PPMS, primary progressive multiple sclerosis; T2DM, type 2 diabetes mellitus; WBCs, white blood cells; y, years.

ccf‐mtDNA appeared to be higher in (i) patients with RRMS compared to other non‐inflammatory/non‐neurodegenerative conditions [ 83 ]; (ii) PMS than other non‐inflammatory diseases and, to a lesser extent, RRMS [ 84 ]; (iii) several neurological disorders (RRMS, PMS, clinically isolated syndrome, inflammatory and non‐inflammatory diseases) compared to HC, without differences among pathologies [ 85 ]. While one study showed a negative correlation of ccf‐mtDNA with the disease duration [ 83 ], another found a positive correlation with T2‐lesions load on MRI and brain atrophy, indicative of a long‐standing disease [ 84 ].

Studies focused on whole‐blood mtDNA‐CN showed (i) reduced levels in RRMS patients compared to HC [ 86 ]; (ii) lower levels in RRMS patients during the remission phase compared to the same patients during relapse [ 87 ]; (iii) higher levels in secondary progressive (SP) compared to primary progressive (PP) MS [ 88 ]; (iv) similar levels in monozygotic twins clinically discordant for MS [ 38 ].

Al‐Kafaji et al. showed that whole‐blood mtDNA‐CN was negatively correlated with disease duration.

Lastly, a recent paper [ 89 ] revealed that mtDNA‐CN correlates with leukocytes telomere length (considered to be an independent factor for conversion to PMS) in RRMS patients with mild–moderate disease, proposing its use as a biomarker of disease‐related disability.

DISCUSSION

The reciprocal relationship between mitochondrial dysfunction and mitochondrial genome integrity in several neurodegenerative diseases has been extensively characterized in the last decades. This has prompted the need to clarify the role of mtDNA as an indicator of the pathogenic mechanisms underlying neurodegeneration. In this review, we systematically collected the evidence on the use of mtDNA as diagnostic and prognostic biomarker in three major neurodegenerative diseases: AD, PD and ALS. Including MS in our research gave us the opportunity to observe the different mtDNA profiles in a condition where neuroinflammation is predominant above neurodegeneration, differently from the other considered diseases [ 90 ].

Specifically, we focused our attention on changes in mtDNA (i) abundance (both as circulating form, ccf‐mtDNA, and as intracellular copy number), (ii) damage/heteroplasmy and (iii) methylation levels. Our aim was to investigate somatic mtDNA changes associated with neurodegenerative processes, rather than the possible causal relationship of each disease with inherited pathogenic mutations.

A recent narrative review summarized the findings of studies investigating whole‐blood mtDNA‐CN in AD, PD, ALS and Huntington's disease [ 91 ]. Another review analysed ccf‐mtDNA in both CSF and blood of patients with various neurological‐nonpsychiatric diseases and found lower values in cases than controls [ 92 ]. Our systematic review has further enriched this landscape since, unlike the previous works, we also considered other mtDNA parameters which are emerging as promising biomarkers of neurodegeneration, such as mtDNA damage, heteroplasmy and methylation in both CSF and blood.

Almost all studies evaluating CSF ccf‐mtDNA found (i) decreased levels in patients with neurodegenerative diseases such as PD and AD, where neurodegeneration prevails over inflammation; (ii) increased levels in MS, where neuroinflammation is predominant. Of note, CSF ccf‐mtDNA data in ALS are currently lacking. On the contrary, the results focused on blood ccf‐mtDNA and intracellular mtDNA‐CN were more contradictory. This discrepancy may be due, at least in part, to differences in the cellular source of mtDNA. Despite the origins of CSF ccf‐mtDNA are still debated, it is conceivable that it is released upon neuro‐axonal injury, glial cell damage or by leukocytes recruited via the choroid plexus [ 43 , 84 , 93 ]. In contrast, the major determinants of blood mtDNA levels are the heterogeneous cell type composition of leukocytes and platelet abundance, which can change with time of day, ageing and disease [ 94 ]. Most of the authors found reduced or unaltered whole‐blood mtDNA levels in PD and AD, increased levels in ALS and increased levels in MS during relapses versus remissions [ 87 ]. This evidence provides proof‐of‐concept that peripheral intracellular mtDNA‐CN (i) is differentially affected across distinct neurodegenerative conditions; (ii) mirrors the activity of pro‐inflammatory pathways.

The general reduction in ccf‐mtDNA and cellular mtDNA levels observed in PD and AD may be secondary to the impaired mitochondrial biogenesis and bioenergetics which characterize both the diseases [ 1 , 95 ]. Reduced mtDNA‐CN were indeed found in nigral dopaminergic neurons isolated from postmortem iPD patients' brain [ 96 ] and in the frontal cortex of AD patients [ 97 ]: these findings suggest that the low CSF ccf‐mtDNA concentration observed in PD and AD may mirror the amount of mtDNA per cell in the brain.

A separate discussion is warranted for monogenic PD, which reflects different underlying biological entities. The higher serum ccf‐mtDNA levels observed in PRKN/PINK1‐PD compared to iPD and HC is likely due to an abnormally increased release of mtDNA by peripheral cells consequent to the impaired mitophagy caused by Parkin or Pink1 loss‐of‐function [ 28 ]. Similarly, the increased CSF ccf‐mtDNA levels found in LRRK2‐PD may be secondary to the altered mtDNA replication, transcription and release associated with LRRK2 mutations [ 98 ]. Overall, these results support the hypothesis that the mechanisms causing mtDNA dysfunction differ between iPD and monogenic PD.

The injection of damaged mtDNA into the brain caused PD dementia (PDD)‐like pathology and led to motor and cognitive dysfunctions in wild‐type mice [ 99 ]. This evidence suggests that mtDNA damage may have a primary role in inducing neurodegeneration awnd cognitive decline in PD. However, two works investigating the correlation between CSF ccf‐mtDNA levels and cognitive function in PD patients found inconclusive [ 43 ] or negative [ 40 ] results. Moreover, blood mtDNA levels [ 29 , 45 , 51 ] and damage [ 54 ] did not correlate with cognitive measures in sporadic PD. Two studies reporting increased serum ccf‐mtDNA levels [ 28 ] and whole‐blood mtDNA damage [ 18 ] in PRKN/PINK1‐PD compared to iPD and HC did not evaluate the association between mtDNA measures and cognitive profile. Considering that cognitive decline is relatively uncommon in PRKN/PINK1‐PD compared to iPD [ 100 ] further research in sporadic and genetic PD populations is needed to elucidate this relevant issue.

Abnormal mitochondrial morphology and dynamics, respiratory chain dysfunction and increased production of reactive oxygen species (ROS) have been described in ALS and variably associated with most of the genes commonly implicated in ALS pathogenesis ( SOD1, TARDBP, FUS, C9ORF72, VCP, SQSTM1, OPTN ) [ 101 ]. In addition, TDP‐43 aggregation, the common pathological feature shared by almost all sporadic and familial ALS cases, has been shown to directly damage mitochondria: TDP‐43 invades mitochondria and leads to increased ROS production and opening of the permeability transition pore, with subsequent leakage of mtDNA into the cytoplasm [ 6 ]. Despite the mechanisms by which intracellular mtDNA is released into the extracellular milieu are still under investigation, this evidence provides the rationale for future research evaluating CSF and blood ccf‐mtDNA levels as putative biomarkers in ALS.

The generally higher CSF ccf‐mtDNA levels found in MS patients compared to controls [ 83 , 84 , 85 ] could reflect the neuronal damage induced by immune‐mediated mechanisms, with consequent release of mtDNA in the extracellular space. Here, mtDNA acts as a damage‐associated molecular pattern (DAMP), which can bind to glial Toll‐like receptor‐9 and trigger a further inflammatory response, in a vicious cycle where mitochondrial dysfunction is both a consequence and a promoter of immune dysregulation [ 10 ]. These findings suggest that while reduced CSF ccf‐mtDNA levels may mirror the chronic undergoing neurodegenerative process underlying PD and AD, high CSF ccf‐mtDNA concentrations may represent a potential biomarker of the acute cellular and mitochondrial stress that characterizes MS.

An interesting parallel is offered by the heterogeneous field of primary mitochondrial diseases (PMDs). Specifically, diseases caused by mtDNA genetic defects (such as mitochondrial encephalopathy, lactic acidosis and stroke‐like episodes, MELAS; Leber's hereditary optic neuropathy, LHON; myoclonic epilepsy with ragged red fibres, MERRF), where the primary dysfunction is related to energy production and mitochondrial protein synthesis, are associated with higher whole‐blood mtDNA‐CN and plasma ccf‐mtDNA levels than HC. Conversely, PMDs caused by nuclear DNA defects are associated with similar or lower levels of the same blood mtDNA measures compared to HC [ 102 , 103 ]. In MELAS and LHON, the increased mtDNA‐CN showed an inverse correlation with disease manifestation and severity [ 104 , 105 , 106 ] and may thus act as a compensatory response triggered by the presence of mutant mtDNA. Moreover, CSF ccf‐mtDNA levels were higher in patients with mitochondrial deletion and depletion syndromes (MDD) compared to those with point mutations in both mitochondrial and nuclear genes involved in energy metabolism, possibly due to different levels of heteroplasmy in CSF‐generating cells or active secretion of dysfunctional mitochondria [ 107 ]. Since ccf‐mtDNA acts as a DAMP, it is not surprising that POLG1 ‐related disease, a cause of MDD, is characterized by chronic central nervous system (CNS) inflammation [ 108 ]. Similarly to what happens during MS relapses [ 87 ], blood ccf‐mtDNA levels increase during the occurrence of “stroke‐like episodes” and status epilepticus in MELAS [ 103 ].

Importantly, the few studies investigating the relationship between disease‐specific treatment and mtDNA levels suggested that (i) dopaminergic drugs downregulate CSF [ 43 ] and whole‐blood [ 50 ] mtDNA levels in PD; (ii) acetylcholinesterase inhibitors upregulate whole‐blood mtDNA‐CN in AD [ 65 ]; fingolimod decreases CSF ccf‐mtDNA levels in MS patients [ 84 ]. Overall, these observations mean that pharmacological treatment may directly affect the CNS and peripheral mtDNA profiles, and should thus be carefully considered in future studies evaluating mtDNA as a potential biomarker in neurodegenerative disorders.

More homogeneous results have been obtained in studies addressing mtDNA variant burden (i.e. deletions, oxidative damage and heteroplasmy levels), which were generally increased in PD and AD compared to HC [ 37 , 54 , 57 , 74 , 75 ]. This observation implies that mtDNA damage may be adopted as a proxy of mitochondrial health independently from the specific biological substrate underpinning mitochondrial dysfunction and neurodegeneration. Furthermore, evidence that mtDNA damage (i) is dependent on ethnicity and sex [ 54 , 74 , 75 ] and (ii) is increased in LRRK2 G2019S asymptomatic carriers compared to healthy non‐carriers [ 54 ], provides proof‐of‐concept for the evaluation of novel tailored mitochondria‐targeted neuroprotective strategies. Only two studies evaluated mtDNA heteroplasmy levels in ALS [ 82 ] and MS [ 38 ], with none specifically aimed at investigating mtDNA damage. Further research is thus required to evaluate whether mtDNA variant burden may serve as a biomarker in these two diseases.

Finally, mtDNA methylation levels were generally reduced in the three neurodegenerative diseases considered compared to controls, while we found no studies evaluating this parameter in MS. In PD and ALS, reduced methylation levels were only observed in specific groups of patients with monogenic forms of the disease [ 53 , 80 , 81 ], whereas in AD initial hypermethylation at the disease onset seems to be followed by decreasing levels during disease progression [ 76 , 77 ]. Apart from the known involvement of the D‐loop region methylation in the regulation of mtDNA transcription and replication [ 80 ], the biological function and regulation of mtDNA methylation are not well‐characterized. Some studies hypothesized that methylation protects mtDNA against oxidative stress during embryogenesis [ 109 ] and modulates the crosstalk between the nuclear and mitochondrial genomes to allow a coordinated gene expression [ 110 ]. However, the link between mtDNA methylation and mitochondrial homeostasis in the field of neurodegenerative diseases remains to be elucidated.

Given the heterogeneity of the studies considered, we cannot draw any definitive conclusion on the diagnostic power of mtDNA in the diseases analysed. However, some studies reported a moderate‐to‐high discriminatory power against healthy subjects in both PD (AUC 0.81 for ccf‐mtDNA [ 29 ], AUC 0.82 for mtDNA damage [ 54 ]) and AD (AUC 0.99 and 0.71 for ccf‐mtDNA [ 30 , 62 ]). Similar considerations apply to its value as a prognostic marker, as most studies found no associations with cognitive or motor features, nor with other markers of neurodegeneration.

Several confounding factors may have contributed to the inconsistency of results among different works. First, only a few studies appropriately selected patients without comorbidities which are known to affect peripheral mtDNA‐CN and/or methylation, such as psychiatric disorders [ 111 ], infections [ 112 ], chronic inflammatory and immune‐mediated diseases [ 113 , 114 ], obesity [ 115 ], cancer [ 116 ], diabetes [ 117 ] and cardiovascular diseases [ 118 , 119 ]. The evidence for altered blood mtDNA profiles in these non‐neurological chronic disorders suggests that the peripheral mtDNA changes summarized in this review are not specific to neurodegeneration, but may instead mirror a common dysregulation of immune and redox homeostasis across different chronic and age‐related diseases [ 120 ]. Second, disease‐specific treatments (e.g. dopaminergic agents [ 43 ], acetylcholinesterase inhibitors [ 65 ] and fingolimod [ 84 ]) could affect mtDNA levels, and this was considered in only a minority of the studies.

Third, age, sex and ancestry may influence mtDNA measurements in both pathological [ 48 , 54 , 74 , 75 ] and physiological [ 121 ] conditions, but few of the included studies stratified participants according to demographic characteristics. Of note, Mengel‐From et al. showed that blood cells‐derived mtDNA‐CN declines during ageing in healthy individuals [ 121 ], but this trend was not observed in PD patients [ 50 ]. One study found higher CSF ccf‐mtDNA levels in older than younger healthy controls [ 30 ], which were not confirmed in subsequent reports [ 41 , 62 ]. However, the observed changes in CSF [ 43 ] and blood [ 29 , 50 ] mtDNA profiles in patients with neurodegenerative diseases compared to controls appeared to be independent of age. While Gui et al. showed lower whole‐blood mtDNA‐CN in late‐onset than early onset PD [ 49 ], other authors found no association between mtDNA‐CN and age at PD onset [ 36 , 52 ]. Asghar et al. showed no correlation between disease duration and whole‐blood mtDNA‐CN in PD, but other studies suggest that blood [ 86 ] and CSF [ 83 ] mtDNA abundance may decline during disease progression in MS. Fourth, the different techniques used for mtDNA analysis, ranging from the traditional qPCR and NGS to the newer ddPCR and TGS, may have contributed to the heterogeneity of results. Owing to their high reliability, sensitivity and constantly reducing costs [ 20 ], ddPCR and TGS will likely be at the forefront of mtDNA research in the future. Lastly, the large majority of studies evaluating blood mtDNA levels did not adjust the analyses for platelet count and leukocyte composition, which represent major determinants of blood mtDNA abundance [ 94 ]. The key relevance of this last factor has been further highlighted by a recently published study evaluating whole‐blood mtDNA‐CN in two distinct large PD cohorts [ 122 ]. This work showed indeed that the association of low whole genome sequencing‐derived mtDNA‐CN with increased PD risk and severity can be predominantly attributed to the different blood cell composition observed between PD and HC populations. These findings suggest that whole‐blood mtDNA‐CN may not be a biomarker of mitochondrial dysfunction in PD, but rather could mirror the altered peripheral immune profile which characterizes PD [ 123 ]. To improve reproducibility, future works evaluating CSF or blood mtDNA profiles should consider all these issues by carefully selecting the study population and considering potential analytical bias (Table  7 ).

TABLE 7 Potential bias and confounding factors in the included studies. Limitation Potential bias introduced in the study Psychiatric and systemic comorbidities not evaluated Possible confounding effect on central and peripheral mtDNA levels and methylation Effect of disease‐related and unrelated pharmacological treatments not evaluated Possible confounding effect on central and peripheral mtDNA levels Statistical analyses not adjusted for demographic data (e.g. age, sex, disease duration) Possible confounding effect on central and peripheral mtDNA levels Different analytical techniques used across studies Potentially limiting reproducibility among studies (see also Table  1 ) Platelet and leukocyte differential count not evaluated Possible confounding effect on peripheral mtDNA levels

Potential bias and confounding factors in the included studies.

Another unmet research need is the analysis of the correlation between CSF and blood ccf‐mtDNA levels. Indeed, we found only one work comparing blood and CSF mtDNA profiles in the same cohort [ 48 ]. This study found similar mtDNA‐CN between PD males and HC males in both CSF and serum. Conversely, PD females showed higher serum mtDNA levels than control females, but statistical analysis was not conducted for CSF due to the lack of available samples in female subgroups. An in‐depth investigation of this issue would allow (i) a valuable insight into the physiopathological meaning of altered peripheral ccf‐mtDNA levels observed by some authors [ 28 , 46 , 48 , 61 ]; (ii) to assess the reliability of blood ccf‐mtDNA as proxy of CNS mitochondrial dysfunction.

Despite these limitations, CSF and blood mtDNA represent promising biomarkers for stratifying patients and subjects at high risk of conversion to manifest neurodegeneration according to a “mitochondrial risk profile”. This would allow the identification of patients with higher probability to benefit from putative mitochondria‐targeted neuroprotective therapies, which are currently undergoing evaluation in clinical trials (Figure  2 ) [ 124 ].

mtDNA sources and measures currently adopted for biomarker discovery in patients with neurodegenerative diseases. Fragments of mtDNA released outside the cell can be detected as ccf‐mtDNA in the CSF, plasma or serum and then quantified as mtDNA concentration (copies/μl). mtDNA isolated from peripheral blood cells is a source of several potential biomarkers for neurodegenerative diseases, including copy number (i.e. the number of mitochondrial genomes per cell), heteroplasmy, damage and methylation levels. By addressing the potential selection and analytical biases which are currently hampering the advancement of mtDNA‐focused research, future studies may enable the use of mtDNA measures as novel diagnostic and prognostic biomarkers. Moreover, the identification of patient clusters characterized by different “mitochondrial risk” profiles may enable a proper selection of patients candidate to receive experimental mitochondria‐targeted treatments (light blue box). Ccf‐mtDNA, circulating cell‐free mitochondrial DNA; CSF, cerebrospinal fluid. Created in BioRender. Valente, E. (2024) BioRender.com/y62h953 .

In conclusion, the value of CSF and blood mtDNA as diagnostic and prognostic biomarkers in the most common neurodegenerative diseases remains to be established through high‐quality studies. A thorough appraisal of the several factors potentially biasing mtDNA profiles and the harmonization of analytical protocols between research laboratories will be crucial to determine if the evaluation of mtDNA may be included in the framework of novel precision medicine strategies in neurodegenerative disorders.

AUTHOR CONTRIBUTIONS

Barbara Risi: Conceptualization; investigation; data curation; visualization; writing – original draft; writing – review and editing. Alberto Imarisio: Conceptualization; investigation; writing – original draft; writing – review and editing; visualization; data curation. Giada Cuconato: Writing – original draft; writing – review and editing. Alessandro Padovani: Writing – review and editing. Enza Maria Valente: Supervision; writing – review and editing. Massimiliano Filosto: Supervision; writing – review and editing.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest related to this manuscript.

Supporting information

Tables S1‐S3.

ACKNOWLEDGEMENTS

No funding was received to assist with the preparation of this manuscript. We thank the Alessandra Bono Foundation for its support to our scientific activity. We are grateful to Prof. Alessandra Valerio for her valuable technical and scientific insights. Barbara Risi, Alessandro Padovani and Massimiliano Filosto are part of the ERN Euro NMD, HCP ASST Spedali Civili, Brescia, Italy.

Risi B, Imarisio A, Cuconato G, Padovani A, Valente EM, Filosto M. Mitochondrial DNA (mtDNA) as fluid biomarker in neurodegenerative disorders: A systematic review. Eur J Neurol. 2025;32:e70014. doi: 10.1111/ene.70014

Barbara Risi and Alberto Imarisio contributed equally and share first co‐authorship.

Enza Maria Valente and Massimiliano Filosto share senior authorship.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

Associated Data

Supplementary Materials

Tables S1‐S3.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.